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If you are planning for a year, sow rice; 
if you are planning for a decade, plant trees; 
if you are planning for a lifetime, educate people.
Chinese proverb

Chapter 1
General Introduction

General Introduction
1.1 Introduction on Renal Cell Carcinoma
Renal Cell Carcinoma (RCC) is the most frequently occurring malignant 
tumor from the kidney in adults, accounting for an estimated 91.000 death 
per year worldwide (g l o b o c a n  2000). This tumor type accounts for 80-90% 
of all primary kidney neoplasms and for about 2% of all malignancies 
(Motzer, 1996). The remaining 10-20% of kidney neoplasms in adults are 
transitional cell carcinomas of the renal pelvis, renal sarcomas, and 
angiomyolipomas. The incidence of RCC is estimated to be 6.8/100,000 
worldwide and in men is almost twice as high as in women (g l o b o c a n  
2000). In both sexes, the incidence increases above the age of 40 years with 
a median age of 65 years (g l o b o c a n  2000).
The incidence of RCC has increased steadily in the past years by 2­
4% per year (Chow, 1999). This can be attributed to a rise in incidental 
discoveries and may be linked to certain environmental risk factors such as 
smoking, obesity, hypertension, treatment of hypertension and exposure to 
chemical products (Motzer, 1996; McLaughlin and Lipworth, 2000). 
Particularly smoking is strongly associated with an increased risk, 
contributing to an estimated 30% of all cases (Motzer, 1996).
The prognosis of patients diagnosed with RCC is heavily dependent 
upon the spread of the disease (Motzer, 1996). Surgery is standard 
treatment for patients with apparent organ confined disease (approximately 
65% of patients diagnosed) (Motzer, 1996). However, 40% of these 
patients relapse after radical tumornephrectomy, usually within one year. 
For the majority of patients with metastatic disease the prognosis is very 
poor, with a median survival of less than one year (Motzer, 1996). 
Chemotherapy, radiotherapy and hormonal therapy are ineffective and 
although immunotherapy with biological response modifiers can lead to 
complete cures, this occurs in less than 10% of patients (Motzer, 1996).
RCC was originally described by Grawitz and is derived from the 
kidney parenchyma. Initially, RCC was considered a fairly homogeneous
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tumor type with diverse growing patterns and cellular morphologies. 
Increased insight in molecular mechanisms leading to RCC lead to a 
subdivision of both the malignant types (common/conventional/clear cell, 
ccRCC, 70-80%; papillary/ chromophilic RCC, 5-10%; chromophobe RCC, 
5% and collecting duct RCC 1%) and benign types (oncocytoma, 3-5%; 
papillary adenoma, 20% and metanephric adenoma) (Kovacs, 1997). This 
division, also known as the Heidelberg classification, is based on 
morphological characteristics and common cytogenetic aberrations in these 
tumors.
1.2 (Molecular) Cytogenetics
It has long been recognized that cancer results from a number of genetic, 
epigenetic and environmental alterations. Alterations in genes involved in 
proliferation, cell cycle control and apoptosis, i.e., genes pivotal for 
regulated cell, tissue and organ growth can lead to uncontrolled cell growth, 
eventually leading to a malignant tumor. Examples of such genes can be 
found in mutator gene, proto-oncogene and tumor suppressor gene 
families.
Alterations in genes associated with carcinogenesis pathways involve 
genetic and epigenetic changes. Traditionally, oncogenes become 
constitutively activated by a pointmutation in one allele (e.g. ras) or 
translocation to a strong promoter (e.g. myc), and tumor suppressor genes 
are inactivated by mutation of one allele and loss of the other allele (Bos, 
1988). This latter hypothesis, referred to as Knudson’s hypothesis, has 
been significantly modified with the discovery of epigenetic mechanisms 
that can alter gene expression i.e. inactivation of a gene by (hyper-) 
methylation. Thus, functional inactivation of both alleles can occur through 
a combination of (point-) mutations, macro- or micro- deletions, macro- or 
micro-insertions and (hyper-) methylation.
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The successful outgrowth of a tumor cell involves alterations in 
multiple genes. The large number of cytogenetic alterations, coupled with 
the morphological and physiological heterogeneity of cancer cells within 
individual tumors, emphasize this. Clinical relevant cancer is the result of 
clonal outgrowth of cells with the most advantageous genetic changes. 
Tumor progression results from successive rounds of mutation and 
selection that leads to more aggressive (sub-) clones.
In many tumor types different cytogenetic alterations can be 
recognized. This heterogeneity has constituted a problem for the discovery 
of genes involved in carcinogenic pathways. Comparison of cytogenetic 
alterations of sporadic tumors has lead to the identification of chromosomal 
regions and genes that are commonly altered in a particular tumor type. 
The characterization of initial genetic hits has further been facilitated by the 
study of genes involved in hereditary cancer syndromes (Zbar and Lerman,
1998).
In RCC, especially the results of Kovacs et al. have contributed 
greatly to a better understanding of common genetic alterations (Kovacs, 
1997). In various elegant studies he and his colleagues showed that RCC 
subtypes identified by different morphologic characteristics have specific 
genetic profiles. In conventional clear cell RCC this is an aberrant 
chromosome 3p that is not observed in other types of RCC (Brauch, 1990; 
Kovacs, 1989). The aberrations of chromosome 3p are clustered in 3 
distinct regions: 3p12-p14, 3p21-p22 and 3p25. In adenomas aberrations at 
3p12-p14 and at 3p25 can be found, suggesting that these chromosomal 
changes are early events, whereas in carcinomas additional aberrations at 
3p21-p22 suggest involvement of this region in progression (Bodmer, 2002; 
Zambrano, 1999; Foster, 1994; van den Berg, 1996; Clifford, 1998; Alimov, 
2000; Martinez, 2000). In general, alterations at multiple 3p regions are 
observed within individual tumors, indicating that multiple genes are 
involved in the ccRCC carcinogenic pathway(s).
11
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Aberrations at chromosome 3p25 had been recognized in Von 
Hippel-Lindau patients that are susceptible to the development of a variety 
of tumors including ccRCC (Maher and Kaelin, Jr., 1997). Linkage analyses 
lead to the molecular cloning of the VHL gene and subsequently the 
frequent inactivation of this gene in sporadic ccRCC was shown (Latif, 
1993; Gnarra, 1994). However, in 11% of sporadic tumors no inactivation of 
VHL can be detected, indicating that in addition to VHL other genes are 
involved in ccRCC carcinogenesis (Table 1). VHL disease and the VHL 
gene will be discussed in further detail in section 1.6 "The Von Hippel­
Lindau Gene”.
In addition to the aberrations observed at 3p25, aberrations at 3p12- 
p14 and 3p21-p22 including interstitial deletions have been reported in 
ccRCC (Foster, 1994; van den Berg, 1996; Clifford, 1998; Alimov, 2000). 
Recently, Martinez et al. showed that 3p12-21 alterations occur 
independently of VHL (Martinez, 2000). Several tumor suppressor genes 
located at these regions have been investigated for their role in ccRCC 
carcinogenesis, including FHIT at 3p14.2 (fragile histidine triad), RASSF1A 
at 3p21.3 (RAS association domain family 1A gene), T^IIR at 3p22 (TGF|3 
type II receptor), DRR1 at 3p21.1 (downregulated in renal cell carcinoma) 
and OGG1 at 3p26.2 (8-oxoguanine DNA glycosylase). These genes will 
be discussed in further detail in section 1.8 "Renal Cell Carcinoma 
Associated Genes".
In addition to the 3p aberrations, duplication of chromosome 5q22 
and deletion(s) of chromosomes 6q, 8p, 9p, 14q and 17p have been 
observed in ccRCC (Kovacs, 1997; Zambrano, 1999). With the exception of 
the loss of 17p, these alterations are characteristic for ccRCC, but are less 
frequent compared with 3p alterations. The loss of 8p, 9p and especially 
14q chromosomal fragments is associated with progression (Zambrano,
1999).
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In the carcinogenic pathway of papillary RCC an adenoma-carcinoma 
sequence has been identified. Papillary adenomas are characterized by 
trisomie of chromosomes 7 and 17 and loss of Y. Progression of these 
tumors into papillary carcinomas result in the accumulation of additional 
chromosomal alterations, including trisomie of 3q, 8, 12, 16 and 20 and loss 
of 9p, 11q, 14q, 21q and 6p (Kovacs, 1997; Zambrano, 1999). The c-Met 
proto-oncogene located on chromosome 7q31.1-34 is one of the genes 
implicated in hereditary and sporadic papillary RCC and will be discussed 
in section 1.4 "(Proto-) Oncogenes”. Recently, a new subgroup of papillary 
RCC characterized by translocations involving chromosome X has been 
recognized (Meloni, 1993; Perot, 1999). Positional cloning identified the 
TFE3 gene as the fusion partner of different genes in these cases of 
papillary RCC. The TFE3 fusion genes will be discussed in further detail in 
section1.4 "(Proto-) Oncogenes”.
RCC of the chromophobe type has been characterized by haploploidy 
of several chromosomes, most notably chromosomes 1, 2, 6, 10, 13, 17 
and 21 (Kovacs, 1997; Zambrano, 1999).
Renal oncocytoma can be subdivided into 4 cytogenetic subgroups: 
many tumors have a normal karyotype, some tumors are characterized by 
loss of chromosome 1p and Y, some tumors by 11q13 alterations and the 
remaining tumors are a cytogenetically very heterogeneous group (Kovacs, 
1997; Zambrano, 1999).
The very rare incidence of collecting duct RCC and the benign 
metanephric adenoma has hindered the establishment of a consistent 
genetic profile up to now.
1.3 Mutator Genes
Based on the general accepted view that cancer is the result of 
accumulation and selection of genetic hits, investigators hypothesized that 
aberrant DNA repair might explain some of the carcinogenic pathways.
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Mutations in enzymes involved in the control of flawless DNA repair and 
replication could lead to increased mutation rates and genomic instability. 
This "mutator phenotype” was observed in particular E.coli strains, and 
subsequently it was shown that this was the consequence of inactivation of 
genes involved in mismatch repair genes (Loeb, 2001).
In human tumors mutator phenotypes are rare, emphasizing that in 
general, mutations in these genes may be incompatible with cell survival 
and growth (Helland, 1997; Cheah, 2000). An elevated mutation rate 
associated with mismatch repair deficiency has been demonstrated in the 
germline from a subset of patients with hereditary non-polyposis colorectal 
cancer (HNPCC) (Jass, 2002; Haydon and Jass, 2002; Muller and Fishel, 
2002). Nevertheless, in general, mutator genes do not seem to play a major 
role in the oncogenic process of human tumors (El Rifai and Powell, 2002; 
Friedlander, 2001; Hruban, 2001; Helland, 1997; Muzeau, 1997; Yang, 
2002; Leach, 2002; Aubry, 2001; Quinn, 1995).
1.4 (Proto-) Oncogenes
Oncogenes were initially described as genes responsible for the 
transforming capability of a number of retroviruses. It was soon realized 
that these viral oncogenes were actually mutated forms of cellular 
homologues (proto-oncogenes). Intense research led to the identification of 
a vast number of proto-oncogenes, most of which are involved in complex 
proliferation pathways, and it was shown that mutational activation could 
lead to initiation of the carcinogenic process. Elegant studies in primary 
fibroblast cells showed that cooperation between two oncogenes was 
required for a transformed phenotype. Based on the former, it was 
suggested that these genes played a major role in tumor formation.
Indeed, activation of (proto-) oncogenes has been described in 
multiple tumors, but with a broad range of incidences (Savelyeva and 
Schwab, 2001). In some sporadic tumor types oncogenes are almost
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invariably activated, indicating an important role in the carcinogenic 
pathway. Examples include c-Abl in chronic myeloid leukemia (CML), K-ras 
in pancreatic and colorectal carcinomas and c-Myc in Burkitt lymphoma 
(Kabarowski and Witte, 2000; Hruban, 2001; Minamoto, 2000; Hecht and 
Aster, 2000).
CML is characterized cytogenetically by a t(9;22)(q34;q11) reciprocal 
translocation resulting in a BCR-ABL gene fusion product (Kabarowski and 
Witte, 2000). This fusion protein displays constitutively elevated tyrosine 
kinase activity that is essential for its transforming abilities (Kabarowski and 
Witte, 2000). Indeed, inhibition of the tyrosine kinase activity has emerged 
as a therapeutic tool (O'Dwyer and Druker, 2000). The oncogenic signal of 
BCR-ABL involves transduction of the tyrosine kinase signal from the 
cytoplasm to the nucleus via intermediary proteins such as ras and myc 
(Sawyers, 1993).
K-ras is a small GTPase that activates the signaling pathway from 
growth factor receptors to the nucleus (McCormick, 1995). Constitutive K­
ras activation, occurring through pointmutation or amplification, can be 
detected in up to 90% of pancreatic cancers and in up to 80% of colorectal 
cancers (Hruban, 2001; Minamoto, 2000).
The myc (proto-) oncogene is a transcription factor that integrates 
proliferation signals and activates cell cycle progression (Nasi, 2001). 
Overexpression of Myc proteins as a result of chromosomal translocations 
or amplifications can be detected in several tumors. The most prominent 
example is Burkitt lymphoma that is characterized by c-myc chromosomal 
rearrangements: the c-myc gene is juxtaposed to immunoglobulin gene 
enhancer elements, leading to an inappropriate transcriptional activation.
In RCC (proto-) oncogenes do not seem to play a major role in the 
carcinogenic pathways with the exception of c-myc. Increased expression 
of this (proto-) oncogene has been reported to occur in up to 75% of 
sporadic RCC (Lanigan, 1993; Weidner, 1990; Kinouchi, 1989; Yao, 1988).
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Enhanced c-myc expression has been correlated with progression, but this 
has not been confirmed by all authors (Kinouchi, 1989; Lanigan, 1993; 
Weidner, 1990; Kozma, 1997; Lipponen, 1995).
In hereditary papillary renal cancer, cytogetically defined by trisomy 7 
and 17 and loss of Y, many patients carry a germline mutation in the c-Met 
growth factor receptor (located on chromosome 7q31.1-34) (Zhuang, 1998) 
(Fischer, 1998) (Schmidt, 1997). The mutations result in a high increase in 
c-MET tyrosine kinase activity that has been shown to be carcinogenic 
(Jeffers, 1997). Interestingly, in the tumors of these patients the mutated c- 
Met allele is duplicated, suggesting that the duplication is the second hit in 
this hereditary carcinogenic pathway (Zhuang, 1998). In contrast to the 
hereditary form, in sporadic papillary RCC mutations in the c-Met proto­
oncogene can be detected in only 13% of cases, indicating that the 
carcinogenic pathways of hereditary and sporadic papillary RCC may be 
different (Schmidt, 1997; Sanders, 2002).
A rare subgroup of papillary RCC is defined by translocations 
involving the TFE3 gene at Xp11.2 (Meloni, 1993; Perot, 1999; Sanders, 
2002; Weterman, 1996; Sidhar, 1996; Clark, 1997; Heimann, 2001). TFE3 
is a transcription factor and fusion to the PRCC protein has been shown to 
elevate its transcriptional activity (Weterman, 2000). In addition, expression 
of the PRCCTFE3 fusion protein interferes with the mitotic spindle 
checkpoint (Weterman, 2001). It has been suggested that the resultant 
aberrant cell cycle regulation may lead in tumor formation in this subgroup 
of papillary RCC.
1.5 Tumor Suppressor Genes
In many malignancies extensive analyses did not reveal involvement of 
distinct (proto-) oncogenes, i.e., they did not seem to play a major role in 
the initiation phase. Investigators realized that genes controlling the cell 
cycle, cell proliferation and/or apoptosis could function as gatekeepers to
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prevent uncontrolled cellular proliferation. Thus, the concept of anti­
oncogenes or tumor suppressor genes was introduced. Complete or partial 
loss of function of these tumor suppressor genes could lead to tumor 
formation.
The first tumor suppressor gene described was the retinoblastoma 
(Rb) susceptibility gene (reviewed in (Marshall, 1991). The identification of 
this gene was facilitated by the existence of a dominantly inherited form of 
Rb. Pivotal linkage studies located the smallest chromosomal defect in 
affected families to chromosome 13q14. Subsequently, this region was 
investigated in greater detail and the Rb gene cloned. Sequence analyses 
of affected family members as well as non-familial, sporadic cases showed 
that both Rb alleles were inactivated, which confirmed Knudson’s 
hypothesis, i.e. that 2 mutational hits are required for the development of 
tumors (Knudson, Jr., 1971). Functional analyses of Rb revealed that it 
regulates the cell cycle G1-S checkpoint by controlling the activity of 
transcription factor E2F (reviewed in (Beijersbergen and Bernards, 1996). 
Phosphorylation of Rb releases this transcription factor permitting 
transcription of genes necessary for the cell cycle G1-S transition. The 
importance of the regulation of E2F activity by Rb is supported by fact that 
the majority of Rb mutations occur in the E2F binding pocket, blocking the 
interaction between Rb and E2F.
After the functional characterization of Rb many other tumor 
suppressor gene products have been identified. In the majority of cases this 
concerns genes that directly or indirectly regulate the cell cycle. The most 
prominent example of a tumor suppressor gene functioning as gatekeeper 
of the cell cycle is p53, functioning in the G1 and G2-M checkpoint controls 
(reviewed in (May and May, 1999). Following cellular stress the level and 
activity of the p53 protein increase as a result of increased synthesis, 
longer half-life and post-translational modifications. It will activate 
transcription of several genes involved in cell-cycle arrest and apoptosis,
17
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permitting DNA repair before cell cycle progression. Obviously, the 
accurate function of this p53 pathway is important to maintain genomic 
integrity.
Patients suffering from the autosomal dominant inherited Li-Fraumeni 
syndrome, molecularly defined as p53 mutated, have an increased risk of 
developing a variety of cancers. In many different sporadic human tumor 
types p53 is mutated or lost in up to 50% of the cells leading to functional 
absence of this quintessential protein (Steele, 1998). In colorectal tumors, 
p53 mutation has been recognized as one of the primary events in the 
transition from benign adenoma to malignant carcinoma (Kirsch and 
Kastan, 1998). In contrast, p53 mutations in superficial bladdercarcinoma 
lead to a malignant, invasive phenotype (Sarkis, 1993). However, p53 
mutational events are not involved ubiquitously in the carcinogenesis of all 
tumor types.
Indeed, in various tumor types p53 mutations are rare (Kirsch and 
Kastan, 1998; Steele, 1998). Nevertheless, p53 may still be involved: e.g. 
through amplification of the mdm2 gene (Kirsch and Kastan, 1998). MDM2 
is one of the major regulators of p53 by sequestering p53 to the cellular 
cytoplasm, thereby preventing specific DNA binding and transcriptional 
activation and leading to protein degradation. Additionally, since some 
transcriptional important pathways are intimately linked, e.g. the Rb and the 
p53 pathway, deregulation of other factors may explain the apparent 
absence of p53 abnormalities in certain tumors (May and May, 1999).
Besides tumor suppressor genes functioning at the cell cycle level, 
tumor suppressor genes can intervene in signal transduction pathways. 
E.g. the adenomatous polyposis coli (APC) gene product controls the 
Wnt/p-catenin/Tcf/Lef signaling pathway that stimulates transcription of 
genes important for proliferation like c-myc, c-jun or cyclin D1 (Behrens, 
2000). Mutations in APC that disrupt control of this signaling pathway have 
been identified as primary event in colorectal tumor initiation (Fodde, 2002).
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The inactivation of the VHL tumor suppressor gene in hereditary and 
sporadic ccRCC tumors suggests a major role for this gene in ccRCC 
carcinogenesis (Latif, 1993; Gnarra, 1994). However, it has become clear 
that in addtition to VHL other genes are involved in ccRCC carcinogenesis 
(Table 1)(Martinez, 2000). VHL disease and the VHL gene will be 
discussed in further detail in section 1.6 "The Von Hippel-Lindau Gene”. 
Other genes implicated in ccRCC carcinogenesis will be discussed in 
furhter detail in section 1.8 "Renal Cell Cacinoma Associated Genes".
Collectively, our current understanding has lead to the conviction that 
tumor-suppressor genes play a prominent role in tumor formation.
1.6 The Von Hippel-Lindau Gene
Patients carrying mutations in the Von Hippel-Lindau gene develop a 
variety of tumors during their life, in particular well-vascularized tumors like 
hemangioblastomas (HAB), pheochromocytomas (PHE) and conventional 
ccRCC (Kondo and Kaelin, Jr., 2001). Recognition of similarities between 
sporadic and familial ccRCC and cytogenetic evidence of the common 
chromosomal changes on 3p25 for sporadic ccRCC suggested the 
presence of a tumor suppressor gene in this area. Linkage analyses of VHL 
affected families delineated this area further and molecular cloning lead to 
the recognition of the VHL gene (Latif, 1993). Analyses of familial and 
sporadic ccRCC cases subsequently showed the involvement of this gene 
in ccRCC carcinogenesis. VHL patients carry a germline mutation in the 
VHL gene and the development of ccRCC is the consequence of somatic 
inactivation of the other VHL allele (Stolle, 1998; Prowse, 1997). Thus far, 
mutational hotspots have not been recognized, but some genotypic- 
phenotypic associations have been recognized (Maher and Kaelin, Jr., 
1997). VHL families may be characterized by the presence (type 2) or 
absence (type 1) of PHE.. Type 2 patients are further subdivided by 
susceptibility to HAB and conventional ccRCC (type 2A, PHE+HAB but not
19
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RCC; type 2B, PHE+ HAB+RCC; type 2C, PHE only). Certain VHL 
mutations are exclusively associated with the type 2C phenotype, certain 
missense mutations with the type 2A phenotype and the type 1 phenotype 
is associated with deletions and protein-truncating mutations (Maher and 
Kaelin, Jr., 1997). However, in general the genotype-phenotype correlation 
is poor.
Table 1. VHL Inactivation in Sporadic ccRCC
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Shuin et al.* 56% ND 84% 71%t 16% 13%
Clifford et al. 42% 14% 86% 31% 31% 38%
Brauch et al. 38% 7% 93% 40% 55% 5%
Hamano et al. 47% 74% 44% 32% 24%
overall 44% 45% 11%
*(Shuin, 1994; Clifford, 1998; Brauch, 2000; Hamano, 2002)
* assuming an average of 8.3% of VHL gene methylation (Herman, 1994; Glavac, 1996;
Clifford, 1998; Brauch, 2000; Morrissey, 2001; Kondo, 2002; Hamano, 2002)
In sporadic ccRCC 40-70% of tumors contain a biallelic inactivated 
VHL gene as detected by LOH, mutation and methylation analyses 
(Table 1). The variability in VHL mutations may partly be explained by the 
use of different techniques, e.g. SSCP vs. direct sequencing, and by 
contamination with normal tissue components. Monoallelic VHL inactivation 
can be detected in 15-55% of cases. Since VEGF overexpression 
correlates with both monoallelic and biallelic VHL inactivation, monoallelic 
VHL inactivation may be sufficient for ccRCC carcinogenesis (Igarashi, 
2002). Even though this would suggest that there is a strict correlation
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between VHL inactivation and ccRCC carcinogenesis, in 11% of sporadic 
tumors no alteration of the VHL alleles can be detected (Table 1). This 
indicates that in addition to VHL other genes are involved in ccRCC 
carcinogenesis, possibly involved in the same signaling pathway as VHL 
(Clifford, 2001a).
Protein analysis of VHL showed that VHL is part of a large protein 
complex, which includes elonginB/C, Cul2 and Rbx1, that functions as an 
E3 ubiquitin ligase (Lisztwan, 1999). The principal target of this complex is 
the hypoxia inducible factor-alpha (HIFa), a transcription factor with a very 
short half-life (approximately 5-20 minutes) that functions in cooperation 
with HIFb (Maxwell, 1999; Cockman, 2000; Tanimoto, 2000). Under 
hypoxic conditions HIFa levels and transcriptional activity dramatically 
increase (Jewell, 2001). The activated HIFa/p heterodimer binds to hypoxia 
responsive elements present in gene promoter regions, leading to 
transcriptional activation of these genes (Semenza, 2000a). Under 
normoxic conditions the VHL complex targets the HIFa transcription factor 
leading to ubiquitination and subsequent degradation by the proteasome 
(Maxwell, 1999). Binding to the VHL complex and subsequent degradation 
of HIFa depend on hydroxylation of proline residues in the degradation 
domain of HIFa (Jaakkola, 2001; Ivan, 2001). Under hypoxic conditions 
HIFa proline hydroxylation is absent, preventing VHL-HIFa interaction, 
leading to the physiologically relevant HIFa levels. Apparently, the VHL 
ubiquitin ligase complex tightly controls HIFa levels and activity.
Thus in ccRCC, the consequence of VHL inactivation is constitutive 
stabilization of HIFa; a mimic of hypoxia (Krieg, 2000; Zhong, 1999). In 
general, this VHL inactivation is considered to be the primary event in 
ccRCC, but insufficient to explain the development of malignant ccRCC. It 
is quite possible that continued upregulation of HIF-directed genes 
eventually leads to metastatic ccRCC (Semenza, 2000b). There is a 
growing number of HIF target genes that are obviously part of the list of
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genes overexpressed in ccRCC (Semenza, 2000b; Wiesener, 2001; 
Young, 2001; Boer, 2001; Takahashi, 2001).
In addition to regulating HIFa availability, VHL also functions in 
fibronectin matrix assembly (Ohh, 1998). Most strikingly, extracellular 
fibronectin matrix assembly by VHL-/- mouse embryos and mouse embryo 
fibroblasts (MEFs) is grossly impaired, supporting a direct role of pVHL in 
fibronectin matrix assembly (Ohh, 1998). This presents the possibility of 
altered integrin signaling that could play a role in ccRCC progression 
(Davidowitz, 2001). In VHL patients all mutations in VHL that lead to 
susceptibility to ccRCC result in both defective regulation of HIFa and loss 
of fibronectin binding (Clifford, 2001b).
Moreover, VHL can bind to transcription factor Sp1 and inhibit Sp1 
dependent transcription (Mukhopadhyay, 1997; Cohen, 1999). Regulation 
of the transactivating properties of transcription factor Sp1 by VHL may 
explain deregulated expression of many genes in ccRCC in addition to 
HI Fa-regulated genes, but has only been demonstrated for VEGF 
transcription.
1.7 Invasion and Metastasis Associated Genes
Although numerous genes have been identified as primary targets in the 
various carcinogenic pathways, it is clear that epithelial tumors develop 
through a multistep process driven by genomic instability. In particular, 
progression to an aggressive, metastatic tumor phenotype requires multiple 
mutational events. This progression from a non-invasive phenotype to 
invasive phenotype is clinically of utmost relevance, as it determines the 
clinical outcome in many cases.
In essence, loss of function or gain of function of metastasis 
associated genes can lead to an invasive tumor phenotype. The primary 
example of a “metastasis suppressor gene” is E-cadherin, member of a 
large family of homotypic cell-cell contact proteins (Wijnhoven, 2000;
22
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Beavon, 2000). Loss of E-cadherin leads to an aggressive, invasive 
phenotype in prostate cancer, bladder cancer and gastric cancer (Umbas, 
1992; Umbas, 1994; Bringuier, 1993; Mayer, 1993). In general the E- 
cadherin-negative tumor population gives rise to the metastatic deposits, 
whereas the E-cadherin positive cells do not metastasize (Umbas, 1992; 
Umbas, 1994).
More recently another metastasis suppressor gene has emerged: the 
Phosphatase and Tensin homologue PTEN (Waite and Eng, 2002). It is a 
lipid and protein phosphatase that antagonizes the phosphatidylinositol 3- 
kinase (PI3K) pathway. Several functions have been attributed to PTEN 
including regulation of growth, apoptosis, adhesion, migration and invasion 
(Leslie, 2001; Liliental, 2000; Tamura, 1999). It plays a particularly 
important role in cell migration and apoptosis after loss of extracellular 
matrix contact, indicating that in tumors loss of PTEN function could lead to 
metastases formation (Lei, 2002; Koul, 2001; Lu, 1999). Indeed, in prostate 
cancer cells loss of PTEN function is strongly implicated in progression 
from androgen-dependence to androgen-independence and in metastatic 
spread (Davies, 2002; Murillo, 2001; Kwabi-Addo, 2001). Furthermore, loss 
of PTEN expression is correlated with progression of cervical carcinoma 
and melanoma (Harima, 2001; Whiteman, 2002; Hwang, 2001; Birck,
2000).
Similarly, gain of metalloproteinase activities may lead to tumor 
invasion and metastases. Metalloproteinases are capable of degrading 
essentially all matrix components enabling tumor cells to migrate (Vihinen 
and Kahari, 2002). In e.g glioma, head and neck carcinoma, breast 
carcinoma, bladder carcinoma and prostate carcinoma expression levels of 
matrix metalloproteinases correlate with invasion, progression and, most 
importantly, patient survival (Binder and Berger, 2002; Werner, 2002; 
Chenard, 1996; Talvensaari-Mattila, 1998; Kanayama, 1998; Wilson and 
Sinha, 1993). Obviously, inhibitors of metalloproteinases have been
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developed and are being tested in clinical trials (Vihinen and Kahari, 2002). 
One randomized study of the matrix metalloproteinase inhibitor marimastat 
has shown some promising results: the 2-years survival increased from 5% 
to 18% in patients with non-resectable gastric and gastro-oesophageal 
adenocarcinoma (Bramhall, 2002). The use of these new drugs as 
adjuvants to (chemo) therapy will probably increase the therapeutic effect 
further.
In ccRCC the identification of invasion and metastasis associated 
genes is highly warranted: 30% of patients diagnosed with organ-confined 
disease will develop metastases within 1 year. Prognostic factors that have 
been identified include aberrant cadherin-6 expression, reduced a-catenin 
expression (part of cadherin complexes), deletion of PTEN and expression 
of matrix metalloprotease 9 (Paul, 1997; Shimazui, 1998; Shimazui, 2000; 
Velickovic, 2002; Slaton, 2001). However, the identification of more specific 
predictors is warranted.
1.8 Renal Cell Carcinoma Associated Genes
As mentioned in section 1.2 "(Molecular) Cytogenetics" genes involved in 
carcinogenic pathways can be classified into mutator gene, proto-oncogene 
and tumor suppressor gene families. For the various RCC types genes 
involved in the carcinogenic pathways of ccRCC and papillary RCC have 
been identified. Specific genes involved in the other RCC subtypes still 
await identification. In ccRCC alterations can be found mainly in tumor 
suppressor genes, whereas in papillary RCC mainly proto-oncogenes seem 
to be involved.
The (proto-) oncogenes c-Met and TFE3 involved in papillary RCC 
carcinogenesis have been discussed in section 1.4 "(Proto-) Oncogenes". 
Since alterations in these (proto-) oncogenes can be detected in only a 
small part of papillary RCC the detection of other genes involved in 
papillary RCC carcinogenesis is warranted.
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In ccRCC carcinogenesis the important role of the VHL tumor 
suppressor gene has been discussed in section 1.6 "The Von Hippel­
Lindau Gene". Since it has become clear that in addtition to VHL other 
genes at chromosome 3p regions are involved in ccRCC carcinogenesis 
various tumor suppressor genes located at these regions have been 
investigated. These include FHIT (3p14.2, fragile histidine triad), RASSF1A 
(3p21.3, RAS association domain family 1A gene), T|3IIR (3p22, TGF|3 type 
II receptor), DRR1 (3p21.1, downregulated in renal cell carcinoma) and 
OGGI (3p26.2, 8-oxoguanine DNA glycosylase).
In the majority of ccRCC FHIT protein expression is absent or 
downregulated compared with normal kidney tissue (Eyzaguirre, 1999; 
Ramp, 2002). Complete absence of protein expression occurs in 50% of 
ccRCC (Hadaczek, 1998). Since this gene is inactivated by deletion and 
mutations are rarely found, FHIT may be involved in ccRCC carcinogenesis 
through haploid insufficiency. However, mice with hemi- or homozygously 
inactivated FHIT are not susceptible to spontaneous or induced 
development of RCC (Zanesi, 2001).
The human RASSFIA gene is inactivated by hypermethylation in 
23%-91% of ccRCC (Dreijerink, 2001; Morrissey, 2001; Yoon, 2001). 
Inactivation of this gene occurs independent of VHL, but is observed in only 
21% of VHL-positive tumors indicating the existence of additional genes 
involved in ccRCC carcinogenesis (Morrissey, 2001). The role of RASSF1A 
inactivation in ccRCC carcinogenesis remains to be established.
In RCC resistance to the antiproliferative signalling of TGF-|31 has 
been observed in 53% of RCC cell lines (Ramp, 1997). However, this 
resistance was not due to inactivation of the T|3IIR gene (Ramp, 1997; 
Cardillo, 2001; Shin, 2000), indicating that other genes of the TGF-|31 
signalling pathway may be involved in RCC carcinogenesis. This is 
supported by the detection of an altered expression of SMAD-2 and SMAD- 
4 proteins in primary ccRCC.
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Wang et al. reported a reduction in DRR1 expression in 68% of 
primary RCC (Wang, 2000). A role for this gene in RCC carcinogenesis 
was further supported by the growth retardation observed by transfection of 
DRR1 into DRR1-negative cell lines (Wang, 2000). It would be interesting 
to determine whether downregulation of DRR1 expression occurs 
independently of VHL and whether downregulation of DRR1 expression is 
an early event in RCC carcinogenesis.
Analysis of 99 primary ccRCC revealed that in only 1 tumor an 
inactivating mutation of the OGG1 gene could be found.(Chevillard, 1998; 
Audebert, 2000). Even though LOH of this region could be detected in 85% 
of ccRCC samples, the markers used in this study imply a concomitant loss 
of the VHL gene (Audebert, 2000). These results do not sustain the 
involvement of OGG1 in RCC carcinogenesis.
It would be interesting to determine whether inactivation of these 
tumor suppresssor genes located at chromosome 3p occur independent of 
VHL. Furthermore, their role in the progression of RCC should be 
established. The results of these analyses will probably reveal genetic 
subgroups of ccRCC with different prognoses.
In addition to these studies focussing on individual genes technical 
advances in molecular biology paved the way for screening many genes 
simultaneously. Differential display, subtractive hybridization or microarray 
analyses may reveal differentially expressed genes. However, these 
techniques can compare gene expression in a limited number of samples 
only, and therefore the significance of individual genes identified must be 
evaluated in larger panels. Furthermore, small but critical changes like e.g. 
loss of one allele of a tumor suppressor gene may not be detected. 
Differential display analyses have revealed a number of up- and 
downregulated genes in RCC in comparison to normal kidney tissue, but 
their relevance and possible use as therapeutic target awaits further study 
(Stassar, 1999; Rae, 2000; Zhang, 2001). Gene expression profiling of
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clear cell RCC on cDNA microarrays revealed a distinct gene expression 
profile between patients with different clinical outcome (Boer, 2001; Young, 
2001; Takahashi, 2001). These interesting results should be evaluated in 
more patients, however. Comparison of gene expression profiles of RCC 
versus patient-matched normal tissue samples (kidney) identified many up- 
(32 genes) and down-regulated (77 genes) genes shared by 75% of RCC 
examined (Takahashi, 2001). These include genes involved in cell 
adhesion, tumor growth, tumor survival, angiogenesis and transcription. 
The large amount of deregulated genes without the existence of gross 
chromosomal aberrations in RCC indicates alteration(s) in the 
transcriptional regulation of these genes.
1.9 Renal Cell Carcinoma Immunotherapeutic Targets
Based on historical clinical evidence RCC is considered an immunogenic 
tumor. In metastasized RCC patients objective spontaneous tumor 
regressions have been observed, highly suggestive for an RCC-specific 
immune response (e.g. (Elhilali, 2000; Chang, 1999; Thoroddsen, 2002; 
Ritchie, 1988). Secondly, treatment with biological response modifiers (IL-2 
and IFN-alpha) can lead to durable responses, whereas other treatment 
modalities fail (Pantuck, 2001; Glaspy, 2002). These anti-RCC responses 
suggest the expression of RCC (specific) targets for the immune system.
Obviously, identification of these targets has been of great interest, as 
they might serve as therapeutic targets. Autologous typing of serum on 
autologous RCC cells lead to the recognition of spontaneous RCC-related 
humoral responses in a minority of patients, but the recognized antigens 
have not been identified (Elhilali and Nayak, 1975; Montie, 1976; Ueda, 
1979; Miller, 1985; deKernion, 1986). Several research groups have 
isolated various cytotoxic T cell (CTL) clones displaying specific cytolysis of 
autologous RCC cells (e.g. (Jantzer and Schendel, 1998; Brouwenstijn, 
1998; Caignard, 1996; Finke, 1994; Koo, 1991; Kurokawa, 2001). In few
27
Chapter 1
cases the RCC specific target recognized by these CTL has been 
determined (Gaugler, 1996; Brandle, 1996; Hanada, 2001). Unfortunately 
these targets are expressed in only a small number of RCC.
To identify RCC specific target(s) various approaches have been 
used. After the description of monoclonal antibody technology, a limited 
number of antibodies that recognize an antigen expressed on RCC and/or 
a specific RCC subtype but with restricted reactivity to normal tissues have 
been described (Oosterwijk, 1986b; Oosterwijk, 1986a; Ueda, 1981; 
Scharfe, 1985; Finstad, 1985; Vessella, 1985; Luner, 1986). Interestingly, in 
comparison with other tumor types the relative proportion of mAbs able to 
discriminate between normal kidney tissue and RCC is rather high. 
Although the restricted tissue distribution of the antigens recognized by 
these antibodies suggests that they may be suitable therapeutic targets, 
molecular identification is lacking for most. The notable exception is 
mAbG250, initially described as mAb recognizing an RCC-associated 
antigen with restricted normal tissue reactivity (Oosterwijk, 1986a). A more 
detailed description of mAbG250 characteristics will be given in Chapter 6.
1.10 Outline of this thesis
The identification and characterization of mAbG250 and its use as 
therapeutic agent in ccRCC prompted us to molecularly identify the G250 
antigen and characterize the mechanism(s) by which expression of this 
gene is activated in ccRCC. Increased understanding of the pathway(s) 
leading to G250 gene activation might lead to additional therpeutic targets if 
e.g., a common pathway could be identified. Additionally, it may lead to the 
recognition of key events in the ccRCC carcinogenic cascade.
Chapter 2 describes the molecular identification of the G250 cDNA 
and gene. Furthermore, the immunogenicity of the G250 antigen in RCC 
patients was investigated.
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The strict correlation between G250 RNA and protein expression 
(Chapter 2) directed the studies toward transcriptional activation 
mechanism(s) (Chapter 3, 4 and 5).
The epigenetic mechanism of differential methylation of the G250 
gene in regulation of G250 gene expression was examined in RCC cell 
lines (Chapter 3). A correlation between G250 gene hypo-methylation and 
G250 expression was observed in vitro. To determine the relevance of this 
phenomenon in vivo studies described in Chapter 4 were initiated. It was 
concluded that in vivo differential methylation is not important for G250 
gene regulation.
Finally, a detailed analysis of the G250 promoter and the transcription 
complex regulating G250 promoter activity was performed (Chapter 5). 
Crucial factors dictating G250 gene expression were identified and the 
transcription complex governing G250 expression in ccRCC unravelled.
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Molecular cloning and immunogenicity of G250
ABSTRACT
The molecular cloning of the cDNA and gene encoding the Renal Cell 
Carcinoma (RCC)-associated protein G250 is described. This protein is one 
of the best markers for clear cell RCC: all clear cell RCC express this 
protein, whereas no expression can be detected in normal kidney and most 
other normal tissue. Antibody studies have indicated that this molecule 
might serve as a therapeutic target. In view of the induction/ upregulation of 
G250 antigen in RCC, its restricted tissue expression and its possible role 
in therapy, we set out to molecularly define the G250 antigen, which we 
identified as a transmembrane protein identical to the tumor-associated 
antigen MN/CAIX. We determined, by FISH analysis, that the G250/MN/CAIX 
gene is located on chromosome 9p12-13. In view of the relative 
immunogenicity of RCC, we investigated whether the G250 antigen can be 
recognized by TIL derived from RCC patients. The initial characterization of 
18 different TIL cultures suggests that anti-G250 reactivity is rare.
INTRODUCTION
The molecular identification of tumor-associated antigens is attracting more 
and more attention, because it is becoming clear that they can be 
immunogenic in humans. Additionally, they can provide clues to important 
carcinogenic events. In Renal Cell Carcinoma (RCC) a number of unique 
renal differentiation antigens as well as several tumor-associated antigens
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(TAA) not expressed in normal kidney (e.g. Oosterwijk et al, 1986; Vessella 
et a,, 1985) have been identified by monoclonal antibody (mAb) technology. 
Molecules of the latter category might be involved in renal carcinogenesis 
and could possibly also serve as targets for T-cells with anti-RCC reactivity.
One of the most extensively studied RCC-associated antigens 
concerns the antigen defined by mAbG250. By immunohistochemistry 
>75% of primary and metastatic RCC express G250 antigen, with virtually 
homogenous, membranous G250 expression in the majority of tumors 
examined (Oosterwijk et al., 1986). In particular clear cell carcinoma RCC, 
comprising approximately 90% of RCC, express G250 antigen (Oosterwijk 
et al., 1995). This contrasts with other RCC-associated antigens, which are 
less abundantly expressed, with no specificity for a defined histological 
RCC subtype. Additionally, G250 antigen is expressed in non-RCC 
carcinomas, albeit at much lower frequency. Normal tissue expression is 
limited to larger bile duct epithelium and stomach mucosal cells (Oosterwijk 
et al., 1995). The G250 antigen expression appears to be induced upon 
malignant transformation of normal kidney cells and can therefore be 
considered as a tumor-associated antigen.
Clinical trials with 131I-labeled mAbG250 in RCC patients have shown 
that the G250 antigen can be used as a therapeutic target (Divgi et al., 1998; 
Oosterwijk et al., 1993; Oosterwijk et al., 1995). In phase I/I I clinical 
radiotherapy trials with 131I-mAbG250 anti-tumor responses have been 
observed (Divgi et al., 1998). Additionally, complete tumor regression was
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observed in animal models when a surrogate G250 antigen, in the form of 
anti-idiotype mAbs, was administered as a vaccine, suggesting that the 
antigen might serve as an immunogenic anti-tumor entity (Uemura et al, 
1994).
Here, we describe the molecular identification of the cDNA and 
gene encoding this unique RCC-TAA and show identity with MN/CAIX, a 
formerly described tumor-associated antigen of the cervix. Additionally we 
show that the occurrence of G250-specific CTL in TIL derived from RCC 
patients is infrequent.
M ATERIALS AND METHODS
cDNA cloning, screening, sequencing and structural analysis of G250 
cDNA and deduced protein sequence
A directionally cloned cDNA expression library was constructed using 
immunoaffinity isolated polyadenylated cytoplasmic RNA from SK-RC-10, a 
RCC cell line with high G250 expression as follows: Total RNA was isolated 
using lithium chloride/urea extraction (Auffray and Rougeon, 1980) 
whereafter poly(A+) RNA was isolated by oligo(dT)-cellulose affinity 
chromatography (Promega, Madison, WI) according to the manufacturers 
instructions. First strand cDNA was synthesized using an oligo(dT) primer­
adapter containing a NotI site 5’ to the oligo(dT) tail (Promega). Seconds 
strand synthesis was performed as described by Gubler and Hoffman 
(Gubler and Hoffman, 1983). The cDNA was blunt ended by T4-DNA
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polymerase (10U), and purified with micro collodion bags (Sartorius GmbH, 
Germany). EcoRI sensitive sites were protected by methylation (EcoRI 
methylase, Gibco BRL, Breda, The Netherlands) performed according to the 
manufacturers instructions. EcoRI-linkers (Stratagene, Cambridge, UK) were 
ligated by T4-DNA ligase, followed by NotI and EcoRI digestion. The 
digested linkers were separated from the cDNA by PurElute™ agarose gel 
electrophoresis (Invitrogen, Leek, The Netherlands) and cDNA of desired 
range (0.5-10 kb) was isolated by electroelution according to the 
manufacturers instruction (Invitrogen). Subsequently the ds cDNA was 
ligated into the pCDM8 vector (Invitrogen), containing an additional EcoRI 
site in the polylinker site and transformed to MC1061/p3 E  coli bacteria.
The library (approximately 300.000 independent transfectants) was 
divided into 9 equal pools, and the plasmids were isolated and transfected 
into COS cells as described (Brakenhoff et al, 1994). Fourty-eight hours 
after transfection COS cells were screened by immunohistochemistry using 
mAbG250 as described (Brakenhoff et al., 1994). After identification of the 
bacterial pool containing the highest number of mAbG250-positive cells, this 
pool was again divided into 10 equal pools and screened. After 3 rounds of 
screening, bacteria were plated, pools of 100 individual colonies were formed 
and screened. Subsequently, pools of 10 colonies, and eventually individual 
colonies were tested.
Subclones of the full length G250 cDNA were isolated using unique 
restriction sites. Sequencing was performed with the dideoxy method using a
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commercially available kit (USB, Cleveland, OH). Additionally, G250-specific 
primers were developed and used for sequence analysis.
RNAse protection analysis was performed to identify the transcription 
start according to the manufacturer’s description (Boehringer Mannheim BV, 
Almere, The Netherlands).
A normal kidney tissue library constructed in the uni-Zap XR vector, 
and subsequently transformed into the host XL1-Blue MRF’ (Promega) was 
screened with full length G250 cDNA as a probe using low stringency 
hybridization conditions.
Computer assisted analysis was performed using IntelliGenetics 
computer software (release 5.4 for Unix). Comparison studies were 
performed with the EMBL nucleotide sequence database (release 51.0). 
Search for protein sequence similarities was performed in the MIPS 
databank with the FastA program (release 34.0).
Northern and Southern blotting
Samples of 10 mg total RNA prepared from cell lines and tissue samples 
were glyoxylated, size fractionated on 1% agarose gels and transferred to 
Hybond N+ nylon membranes (Amersham, Buckinghamshire, UK). Genomic 
DNA was prepared according to Sambrook et al. (Sambrook et al., 1989), 
digested with different enzymes, resolved on an agarose gel, transferred to 
Hybond N+ nylon membranes and fixed by UV-irradiation.
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pMW2 (G250 cDNA fragment covering bp 1-1228) was labeled by 
random priming (Feinberg and Vogelstein, 1983) with 32P dATP and used as 
probe. Hybridization was performed under high stringency conditions.
For quantitation purposes, blots were exposed on a 32P-exposure 
platform connected with a Biorad GS-363 imager (Biorad, Veenendaal, The 
Netherlands)
Isolation of genomic G250 sequences
A Lambda-fixII library that was constructed using human placental DNA 
(Stratagene, Cambridge, UK) was screened to obtain G250 genomic 
sequences. 0.8 x 106 recombinant lambda phages were plated and screened 
using 32P-labeled pMW2 (bp 1-1228) as probe. High stringency hybridization 
was performed in 50% formamide/5xSSC at 42 oC overnight, followed by 
washes with 2x SSC/0.1% SDS, 0.1x SSC/0.1% SDS (both at 42 oC) and 
0.1x SSC/0.1% SDS at 65 oC. After overnight exposure, positive plaques 
were isolated and purified to homogeneity by subcloning.
A physical restriction map for the enzymes SmaI and PstI was 
obtained by digestion of different phage clones. The DNA fragments were 
isolated and inserted into appropriate vectors. DNA sequencing and 
alignment of these inserts revealed several gaps in the physical map. 
Therefore, PCR products amplifying regions of interest were cloned and 
sequenced. If necessary, e.g., because the intron-exon boundaries were not 
resolved, subclones were isolated
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Affinity purification and Western blot analysis
Purified mAbG250 was coupled to affigel-10 beads (Biorad, Veenendaal, 
The Netherlands), according to the manufacturers' instructions. Cell lysates 
from mAbG250-positive cell lines or from Sf9 cells infected with G250- 
baculoviral vectors were incubated with the mAbG250-affinity beads for 4 
hours. The beads were washed and bound protein eluted with 0.1 M 
triethylamin, pH 11.0. The eluted material was evaluated by PAAGE and 
Western blot as described by Towbin et al (Towbin et al., 1979).
Generation and analysis of stable G250 transfected cell lines 
pMW1 was cloned into the Xbal Notl restriction sites of pBJ1neo (variant of 
pcDL-SRa296, kind gift of Dr. R. de Waal-Malefijt, DNAX, Palo Alto, CA) 
resulting in pMW1neo. Cell lines were transfected with pMW1neo or 
pBJ1neo (vector only, mock transfection) using lipofectin (Gibco, Breda, 
The Netherlands) or DOSPER (Boehringer Mannheim B.V, Almere, The 
Netherlands) after determination of G418 (Gibco, Breda, The Netherlands) 
sensitivity of the parental cell lines according to the manufacturers 
instruction. The following cell lines were investigated: SK-RC-12, SK-RC- 
17, SK-RC-59, SK-RC-26b (mAbG250-negative RCC cell lines). Individual 
transfectants were isolated, expanded and investigated.
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FACS analysis
Cells were harvested by a brief trypsinazation or EDTA incubation, followed 
by incubation with mAb. After 45 minutes cells were washed with PBS 
(50mM phosphate, 0.9% NaCl), and incubated with goat-anti-mouse FITC 
(American Qualex, Mt. Vermon, Indiana). After 30 minutes, cells were 
washed with PBS and fixed with 1% paraformaldehyde. Samples were 
investigated on a Coulter Epics flowcytometer. Isotype matched control 
mAbs were included to correct for background staining.
TIL Cell culture
The melanoma cell line, BLM (Bakker et al., 1994), and the transfected cell 
line BLM-G250 were cultured in Dulbecco's modified eagle medium 
(DMEM, Gibco, Breda, The Netherlands) enriched with 5% FCS and 
antibiotic-antimycotic. The transfected cell line BLM-G250 was cultured in 
the presence of G418 (1 mg/ml, Gibco). The transfected SKRC cell lines 
were cultured in RPMI-1640 (Gibco) enriched with 10% FCS and antibiotic- 
antimycotic in the presence of G418 (0.6 mg/ml; Gibco).
Isolation and culturing of RCC-derived TIL
RCC-derived TIL isolated from patients of three different hospitals were 
tested for anti-G250 reactivity. Primary TIL from UCLA, Los Angeles, CA 
were kindly provided by Dr. A. Belldegrun (1988) and were cultured in the 
presence of 200-400 U IL-2/ml (Cetus, Emeryville, CA) for 2-3 weeks. TIL
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cultures from the Ludwig-Maximilians-Universitat, Munich, Germany, were 
cultured in 24-well plate in the presence of 20 U IL-2/ml (Cetus) for 
approximately 14 days as described previously (Schendel et al., 1993). 
Primary TIL obtained at the university hospital in Nijmegen, The 
Netherlands, were prepared as follows: RCC material was minced into 
small pieces and lymphocytes were isolated using Ficoll-density 
centrifugation. The lymphocytes (5 x 105/ml) were stimulated with 1 mg/ml 
aCD3 and 1 mg/ml aCD28 (Van Lier et al., 1991) in Iscoves medium with 
7.5% human serum (HS). After 2 days, 20-50 U/ml IL-2 (Cetus Corp.) was 
added to the lymphocyte-cultures and at day 7 the lymphocytes received 
fresh Iscoves medium with 7.5% HS and 20-200 U/ml IL-2 (Cetus Corp.). 
The responder TIL were stimulated with IL-2 for 21 days.
Cytotoxicity assay
CTL activity was assayed using four hour chromium release assays as 
described previously (Bakker et al., 1994). Briefly, 106 target cells were 
incubated with 100 mCi Na2[51Cr]O4 (Amersham, Bucks, UK) for 45 min at 
37°C. After extensive washing, chromium-labeled target cells were mixed 
with unlabeled K562 cells (ratio 1:10). Effector cells were added to 103 
chromium-labeled target cells and after four hours 100 l^ of the supernatant 
was harvested and the radioactivity was measured. Experiments were 
performed in triplicate. The specific chromium release was defined by:
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[(experimental release - spontaneous release (SR)) / (maximum release - 
SR)] x 100%.
R ESU LT S
Cloning of G250 cDNA
Screening of a cDNA expression library by immunohistochemical means 
(Brakenhoff et al., 1994), resulted in the isolation of a cDNA clone, 
designated pMW1, with an insert of approximately 1.5 kb. This putative 
G250 cDNA was used as a probe for Northern analysis of mRNA isolated 
from RCC cell lines (mAbG250+ and mAbG250-), surgical specimens (RCC 
and normal kidney obtained from the same patients), and normal human 
organs (fetal kidney, adult kidney cortex and kidney medulla, liver, colon, 
placenta, muscle, prostate, spleen) for which the reactivity with the mAb 
recognizing G250 antigen had been determined. After hybridization under 
stringent conditions a single 1.5 kb transcript was detected in all mAbG250- 
positive cell lines and RCC specimens (Fig. 1A,B), whereas no reactivity 
was detected in all mAbG250-negative specimens. The complete 
correlation between G250-mRNA expression as detected by cDNA pMW1 
and G250 protein expression as detected by mAbG250 suggests that 
pMW1 indeed encodes G250 antigen. The size of the of the cDNA insert 
(1.5 kb) corresponds to the size of the mRNA detected by Northern blot 
analysis suggesting that the cDNA clone is full length.
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Figure 1. Northern blot analysis of RNA isolated from (A) paired normal 
kidney/RCC specimens and fetal kidney; (B) human RCC cell lines. Probing 
with pMW2 revealed a 1.5 kb transcript in all G250-antigen positive specimens. The 
results of probing with an rRNA-specific probe are presented to show loading 
differences.
G250-negative cell lines were stably transfected with the putative 
G250-encoding cDNA and investigated by FACS analysis. Indeed, 
transfection with pMW1 lead to strong expression of mAbG250- 
recognizable protein (Fig. 2), providing unequivocal evidence that the 
isolated cDNA indeed encoded for this antigen.
A mAb G250 
mock pMW1
B mAb M75
mock pMW1
Figure 2. FACS analysis of the pMW1 transfected cell line SKRC-17 using 
(A) mAb G250 and (B) mAb M75. Strong staining is observed irrespective of 
mAb used. Mock - pBJ1neo transfectant; pMW1 - pMW1neo transfectant.
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Sequence analysis
Nucleotide sequence analysis of the G250 cDNA revealed that it consists of 
1519 bp (accession number DS 35472) and contains an open reading 
frame (ORF) of 1380 bp, starting at position 10, with an ATG that is in good 
context (GCCGCATGG) with the rule proposed for translation initiation 
(Kozak, 1989). RNAse protection assays revealed that the most prevalent 
transcript is actually 22 nucleotides longer than the isolated cDNA (results 
not shown). Thus the transcription start site is located 32 nucleotides 
upstream from the proposed ATG start site. The AT rich 3' untranslated 
region contains a polyadenylation signal (AATAAA) preceding the end of 
the cDNA by 16 bp, as well as an ATTTA motif that may contribute to 
mRNA instability (Shaw and Kamen, 1986). As expected the 3' untranslated 
region included a poly(A) tail. Computer aided database analysis revealed 
that the G250 cDNA sequence was identical to MN/CAIX (accession 
number Z 54349), a cervical carcinoma-associated antigen initially defined 
in HeLa cells and recently shown to be expressed by RCC (McKiernan et 
al, 1997; Opavsky et al, 1996).
FACS analysis of the aforementioned G250 transfectants with 
mAbM75, a mAb recognizing MN, showed that indeed transfection with 
pMW1 lead to a conversion to a MN-positive phenotype, corroborating the 
identity of the two antigens (Fig. 2). Additionally, purification of baculovirally 
produced G250 antigen by mAbG250 affinity chromatography followed by
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Western blot analysis with M75 showed strong staining of the purified 
product, again emphasizing the identity of both antigens (data not shown).
Southern blot analysis
As described for MN, Southern blot analysis of human chromosomal DNA 
showed that the G250/MN/CA|X gene is present in the human genome as a 
single copy gene of approximately 7.2 kb. Amplification of G250-encoding 
genomic DNA was not observed in any of the surgically obtained RCC 
specimens or RCC cell lines. The genomic organization of the G250 gene 
was identical to MN/CAIX (Fig. 3) (Opavsky et al, 1996).
1 2 3 4 5  6 7 8 9 1 0 1 1
No differences were observed between the genomic and cDNA 
sequence, with the exception of an A-G transition of nucleotide 106, 
resulting in a shift of methionine to valine. To test whether this mutation 
concerned a natural polymorphism or mutation, Polymerase Chain 
Reaction-Single Strand Conformation Polymorphism (PCR-SSCP) analysis
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of 10 RCC/normal kidney pairs using exon 1 specific primers was 
performed. No mobility shifts in DNA fragments in RCC tissue as compared 
to the normal kidney counterpart were observed (results not shown), 
indicating that this transition concerned a natural polymorphism. Sequence 
analysis revealed that both alleles are functional.
Fluorescent in situ Hybridization
FISH analysis showed that the G250/MN/CAIX gene is located on 
chromosome 9p12-13. This region has not been implicated in the 
carcinogenesis of RCC.
Immunogenicity of G250
To investigate whether the RCC-associated antigen G250 is able to 
activate an immune response in patients, TIL isolated from 18 primary RCC 
were tested for their ability to lyse a panel of G250 transfected cell lines. 
These cell lines were selected because they had up to three HLA- 
molecules in common with the TIL, predominantly HLA-A2, HLA-B7 and 
HLA-B8, and HLA-Cw7. Phenotypic analysis showed that the TIL cultures 
contained 60-95% CD3+/T cell receptor ab+ T cells. The percentage of 
CD4+ and CD8+ T cells was highly variable, e.g. TIL UCLA-187 contained 
80% CD4+ T cells and 10% CD8+ T cells, whereas TIL AZN-12 contained 
5% CD4+ T cells and 90% CD8+ T cells. Several of the TIL tested showed 
specific reactivity against the tumor cell lines used (Table I). TIL IIUM-39
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lysed all cell lines tested, whereas other TIL specifically recognized only 
one tumor cell line (e.g. TIL UCLA-187). One TIL (IIUM-35, 65% 
CD3+/CD8+) demonstrated preferential lysis of the SKRC-12/G250 
transfectant. However, subsequent cloning of this TIL by limiting dilution did 
not result in a CTL clone capable of lysing the SKRC-12/G250 target cells 
in a G250-dependent manner.
Table 1. Anti-G250 Reactivity Of RCC-Derived Til
TIL
BL
M
Gp
10
0
BL
M
G2
50
SK
RC
-1
2
m
oc
k
SK
RC
-1
2
G2
50
SK
RC
-1
7
m
oc
k
SK
RC
-1
7
G2
50
SK
RC
-5
9
m
oc
k
SK
RC
-5
9
G2
50
UCLA-781 0 0 - - - - - -
UCLA-94* 0 0 - - 0 0 - -
UCLA-144* 0 0 - - 0 0 - -
UCLA-187 - - 17 17 0 0 - -
UCLA-200* 0 0 18 4 8 8 0 0
IIUM-223 - - - - 14 14 - -
IIUM-29 5 7 - - 22 19 20 8
IIUM-31 0 0 2 3 1 1 0 0
IIUM-34 0 0 2 0 0 0 0 0
IIUM-35* 3 1 13 22 9 8 6 6
IIUM-39* 4 2 22 20 12 12 18 7
IIUM-42* 0 0 1 0 0 0 0 0
IIUM-50* 3 0 3 4 5 3 7 4
AZN-11 - - - - 0 0 - -
AZN-2* 0 0 - - 25 25 - -
AZN-8* 0 0 - - 0 0 - -
AZN-11* 3 2 - - - - - -
AZN-12* 2 0 - - 45 30 - -
1 E:T ratio is 100:1
2 -, not tested
3 E:T ratio is 8:1
* TIL contained > 50% CD8+ T cells.
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DISCUSSIO N
In this report we describe the molecular identification and characterization 
of the RCC- associated antigen G250. Immunohistochemical screening of 
progressively smaller pools of transfectants lead to the identification of a 
1.5 kb cDNA insert. Probing of Northern blots of surgical RCC specimens 
with this insert showed a 1.5 kb transcript in RCC specimens whereas no 
transcript was detected in mRNA obtained from the corresponding 
uninvolved kidney. Additionally, a 1.5 kb transcript was observed in 
mAbG250-positive RCC cell lines, but not in mAbG250-negative cell lines 
or in normal human tissues. Transfection of G250-negative cell lines with 
the putative G250-encoding cDNA resulted in homogeneous, strong 
reactivity with the mAbG250, substantiating the notion that this cDNA 
encoded for G250 antigen.
Sequence analysis showed that the predicted G250 protein contains 
a signal peptide (aa 1-37), a hydrophobic transmembrane region of 20 aa, 
a small cytoplasmic portion of 25 aa and a large extracellular portion with 
high homology to carbonic anhydrase VI (40.2% at the protein level). A 
computer aided database search revealed complete identity with MN 
(accession number Z 54349), a human tumor-associated protein, originally 
identified in HeLa cells using mAb M75 (Opavsky et al, 1996; Pastorek et al, 
1994). This antigen has been implicated as a promising target for cervical 
carcinoma therapy (McKiernan et al., 1997). The immunohistochemical 
distribution of G250 and MN appears to be identical and Western blots 
probed with M75 mAb (specific for MN antigen) after mAbG250 affinity
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purification revealed reactivity to the purified protein. Thus, these important 
TAA independently identified in two different tumor types are identical.
The genomic organization of the G250 gene was identical to 
MN\CA|X (Opavsky et al., 1996). Genomic mutations were not observed in 
RCC. Genomic sequencing revealed a A ®G  transition in codon 33 of exon 
I (nucleotide 106), leading to a change of methionine to valine. PCR-SSCP 
analysis of DNA isolated from 10 paired RCC/normal kidney specimens did 
not reveal any mobility shift in RCC-derived DNA fragments compared to 
normal kidney derived DNA fragments, indicating that the transition 
represents a naturally occurring polymorphism.
By FISH analysis using a genomic clone containing the 5' end of the 
G250 gene, the G250 gene was located at 9p12-13. This location does not 
correspond to any LOH locus previously indicated in RCC. However, this is 
not unexpected since G250 expression is clearly induced upon malignant 
transformation, i.e., it has oncogene like characteristic, whereas LOH 
studies are designed to identify putative tumor-suppressor loci. Moch et al. 
found a significant correlation between loss of chromosome 9 and tumor 
recurrence in 41 nonmetastatic clear cell RCC (Moch et al., 1996). These 
investigators suggested that a tumor suppressor gene on chromosome 9p 
may play a role in RCC progression. Although we have not studied LOH 
and G250 expression simultaneously, is appears that LOH of chromosome 
9p does not influence G250 expression: G250 protein expression is found 
in virtually all clear cell RCC, including metastatic lesions.
The precise details of genetic changes in renal proximal tubular 
epithelial cells leading to the development of RCC are not well understood.
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Recent studies characterizing genetic aberrations in RCC have implicated a 
number of chromosomal loci as important in renal cancer development and 
progression (Fleming, 1998). Lubensky et al., have shown that mutations in 
the tumor suppressor gene responsible for Von Hippel-Lindau (VHL) 
disease, an autosomal dominant inherited familial cancer syndrome, can be 
detected in microscopic RCC in situ obtained from VHL patients, 
suggesting that all clear cell RCC lesions, including these microscopic 
lesions, represent neoplasms and that loss of functional VHL occurs very 
early in their development (Lubensky et al., 1996). Similarly, the event 
leading to G250 antigen expression is an early event in the malignant 
transformation of proximal tubular cells: homogeneous G250 expression 
was observed in all cells of very small clear cell RCC adenomas (0.2-2 cm 
diameter lesions in cadaver kidneys, E. Oosterwijk, pers. observ.). It is 
possible that a direct causal relationship exists between loss of functional 
VHL and G250 gene activation.
In our earlier studies we speculated that external virus-like agents 
might be involved in the carcinogenesis of RCC (Oosterwijk et al., 1986). 
The expression of G250 in RCC as well as in cervical cancers, the latter as 
revealed with mAb M75, is intriguing in view of the role that HPV viruses 
play in the onset of cervical cancer (reviewed by Bosch et al., 1995). 
Additionally, G250-upregulation was found in lymphocytic choriomeningitis 
virus (LCMV)-infected HeLa cells (Pastorek et al., 1994). We have not been 
able to detect any HPV or HPV-like viruses in mAbG250-positive bladder 
tumors by HPV-specific RT-PCR (results not shown). Nevertheless,
60
Molecular cloning and immunogenicity of G250
upregulation of G250 antigen in RCC may be caused by infection by an as 
yet unidentified virus leading to e.g., different transcriptional regulation
The relative immunogenicity of RCC and the existence of RCC- 
specific MHC-restricted CTL in RCC patients (e.g. Schendel et al., 1993) 
appear to indicate that RCC express antigenic determinants that can 
generate tumor-specific immune responses. It is possible that the G250 
antigen is a target for RCC-specific CTL. Therefore we have investigated 
whether G250-specific CTL could be detected in TIL cultures of RCC 
patients. Initial screening of 18 RCC derived TIL yielded one TIL (IIUM-35) 
that preferentially lysed a G250 transfected target cell. Unfortunately, 
cloning attempts to unequivocally demonstrate that IIUM-35 recognized a 
G250 derived peptide was unsuccessful. These data suggest that among 
the TIL tested the G250 antigen is not a major target. However, we cannot 
exclude that the target cell lines present highly immunogenic G250 
peptides in (a) allogeneic MHC-class I molecule(s), which are not 
recognized by the TIL. Preliminary data of induction of G250 reactive CTL 
using peptide loaded dendritic cells suggest that the G250 antigen might 
server as a target for T-cells with anti-RCC reactivity.
In summary, the molecular identification of the RCC-associated 
antigen G250 revealed identity to the cervical carcinoma-associated 
antigen MN/CAIX. The gene was localized on chromosome 9p12-13. 
Additionally we showed that in the approach used detection of TIL with 
G250-specific reactivity is rare.
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Methylation of G250 gene in vitro
ABSTRACT
The MN/CA9 (G250) gene expressed in the normal alimentary tract in a 
tissue specific manner is often activated in renal cell carcinomas. To cast 
light on the activation mechanism, we examined the methylation status of 
this gene in seven human renal cell carcinoma cell lines (SKRC-01, -06, - 
10, -12, -14, -44, and -59) and three normal kidney tissue samples using 
the bisulfite genomic sequencing protocol. CpG methylation was measured 
at seven locations in the MN/CA9 5’region. MN/CA9 transcripts were 
detected by reverse transcription-polymerase chain reaction in five of the 
renal cell carcinoma cell lines (SKRC-01, -06, -10, -44, and -59). These 
MN/CA9 positive cell lines showed hypomethylation, whereas the 
remaining two cell lines (SKRC-12, and -14) and three normal kidney tissue 
samples without transcripts demonstrated hypermethylation. Treatment 
with the demethylating agent 5-aza-2’-deoxycytidine resulted in activation 
of the MN/CA9 gene in the negative cell lines (SKRC-12 and -14). These 
data suggest that hypomethylation in the 5’ region may have a major role in 
expression of the MN/CA9 gene in renal cell carcinoma cells.
INTRODUCTION
It is known that most human renal cell carcinoma (RCC) cells express an 
antigen recognized by a monoclonal antibody G250 [1]. This antigen is 
localized on the surface and in the cytoplasm of RCC cells, whereas its
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expression in normal tissues is restricted to the cytoplasm in gastric 
mucosa and large bile duct cells [1]. Molecular cloning has recently 
revealed that this antigen is homologous to MN, originally identified in HeLa 
cells as a member of the carbonic anhydrase family with apparent 
molecular weights of 58 and 54 kDa [2, 3]. In an immunohistochemical 
study, approximately 90% of RCC specimens (128/147) showed MN 
expression compared to no expression in corresponding normal kidney [4]. 
It has been shown that MN can induce a malignant phenotype in NIH3T3
[2]. Although MN may be useful as a target molecule of immunotherapy for 
RCCs [5] and as a biomarker of RCCs, cervical carcinomas and colorectal 
tumors [4, 6-8], the mechanism of activation of the MN coding gene, 
MN/CA9, remains unclear. Sequence analysis has demonstrated that there 
is no difference between normal tissue and tumor derived MN/CA9 cDNAs
[9], indicating that MN/CA9 activation in malignant tissues may depend on 
altered control rather than mutations.
The importance of DNA hypomethylation for gene expression is well 
established for some genes linked to cancer. Demethylation and 
overexpression of the c-fos, c-myc and c-Ha-ras proto-oncogenes is known 
to be involved in hepatocarcinogenesis induced by conditions such as 
methyl-donor starvation [10]. Other genes, like ornithine decarboxylase and 
the erb-A1 and bcl-2 proto-oncogenes, have been reported to be 
hypomethylated in chronic lymphocytic leukemia [11, 12]. Activation of the
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MAGE-1 gene, which encodes tumor-specific antigens in melanomas, also 
seems to be due to demethylation of the promoter [13]. Thus DNA 
methylation has been suggested to contribute to the regulation of gene 
expression, and CpG methylation in regulatory regions can influence 
transcription directly by interfering with the binding of positively or 
negatively acting transcription factors or indirectly by the formation of 
inactive chromatin [14]. With tissue specific genes, hypomethylation of 
specific DNA regions, usually close to the promoter, is frequently found in 
those cells or tissues demonstrating expression [15].
For the present study, we postulated that the methylation status of 
CpG in regulatory regions might affect expression of the MN/CA9 gene in 
RCCs. Thus, we examined the correlation between MN/CA9 gene 
expression and methylation status in the 5’ region of this gene overlapping 
with the promoter, using human RCC cell lines. In addition, we evaluated 
the effect of a demethylating agent, 5-aza-2’-deoxycytidine on MN/CA9 
expression.
M ATERIALS AND METHODS 
Cell Lines and 5-Aza-2’-Deoxycytidine Treatment
Seven human RCC cell lines (SKRC-01, -06, -10, -12, -14, -44, and -59) 
were maintained in RPMI1640 supplemented with 10% fetal calf serum
[16]. As normal control samples, three non-cancerous counterparts of the
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kidneys with small tumor were obtained from patients who had undergone 
nephrectomy at Nara Medical University Hospital and consented to the 
study. To investigate induction of MN/CA9 expression by treatment with a 
demethylating agent, two RCC cell lines (SKRC-12 and -14) were 
incubated for 3 or 7 days in culture medium containing 1|iM 5-aza-2’- 
deoxycytidine (Sigma, St. Louis, MO).
RT-PCR
Total RNAs were isolated from the cell lines and tissue samples using an 
ISOGEN kit (NIPPON GENE, Toyama, Japan). RT-PCR was performed to 
estimate MN/CA9 expression. First-strand cDNA synthesis was achieved 
using 1mg aliquots of total RNA in 20ml reaction buffer containing 5mM of 
oligonucleotide primers (Oligo(dT)12-18 Primers, BRL, Gaitherburg, MD) and 
200U of reverse transcriptase (Superscript II M-MLV RNase H- reverse 
transcriptase, BRL) at 42 °C  for 50 min. PCR primers for MN/CA9 cDNA 
amplification were designed to cover the 495 bp region from exons 1 to 3 
(sense: 5’-ACTGCTGCTTCTGATGCCTGT-3’ , antisense: 5’-TCCCGCCGCTCCC 
AGAACT-3’). PCR amplification was carried out in 50-ml reaction mixtures 
containing 1ml cDNA in 10mM Tris-HCl pH 8.3, 50mM KCl, 1.5mM MgCl2, 
0.5mM each primer, 0.2mM dNTPs and 0.5U Taq DNA polymerase 
(AmpliTaq Gold, Perkin-Elmer Cetus, Norwalk, CT). Samples were heated 
at 95°C for 9 min and subjected to 30 cycles of PCR consisting of 2 min at 
95°C, 2 min at 68°C and 1 min at 72°C.
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To evaluate MN/CA9 activation by 5-aza-2’-deoxycytidine treatment, 
nested RT-PCR was carried out on SKRC-12 and SKRC-14 with or without 
this treatment. The first PCR amplification was performed under the 
aforementioned conditions, decreasing the PCR cycles from 30 to 25. 
Nested PCR amplification was achieved using 0.5ml of first PCR reaction 
mixture as a template under the following conditions: 95°C for 9 min for one 
cycle; 95°C for 1 min, 54°C for 1 min, and 72 °C for 1 min for 20 cycles 
(sense: 5’-CGGATGCAGGAGGATTC-3’, antisense: 5’-GTCTCAGTAACCGCGATA- 
3’). Nested RT-PCR resulted in a 309-bp fragment. The PCR products were 
electrophoresed on 1% agarose gels and stained with ethidium bromide. b- 
actin cDNAs were amplified as the internal control.
Bisulfite Genomic Sequencing Protocol
Genomic DNAs were extracted from the cell lines and tissue samples as 
described previously [17]. The bisulfite genomic sequencing protocol was 
employed to investigate the CpG methylation status, following the protocol 
detailed in previous reports [18]. In brief, 2-mg aliquots of genomic DNA 
were digested with 20U of EcoRI, purified with phenol-chloroform- 
isoamylalchol, and resuspended in 20ml of TE buffer. After denaturation by 
adding freshly prepared NaOH to a final concentration of 0.3M and 
incubation for 15 min at 37°C, the DNA was incubated in a total volume of 
1200ml with freshly prepared 2M sodium metabisulfite (Sigma) and 0.5mM
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hydroquinone (Sigma), pH5.0, under mineral oil at 55°C for 16 h. Samples 
were purified using desalting columns (Microcon 100, Amicon, Inc., 
Beverly, MA) and incubated with freshly prepared NaOH to a final 
concentration of 0.3M at 37°C for 15 min. The DNA was then ethanol 
precipitated and resuspended in 20ml of TE buffer.
PCR primers for the bisulfite-modified MN/CA9 gene were designed 
for the 5’ region (nt -142 to +267). First PCR amplification was performed in 
20-ml reaction mixtures containing 3ml of bisulfite-treated genomic DNA, 
10mM Tris-HCl pH 8.3, 50mM KCl, 1.5mM MgCl2, 0.5|iM each primer, 
0.2mM dNTPs, and 0.5U Taq DNA polymerase (BRL) under the following 
conditions: 94°C for 1 min, 50°C for 2 min, and 72°C for 3 min for five 
cycles and 94°C for 0.5min, 50°C for 1.5min, and 72°C for 1.5min for 30 
cycles (sense: 5-TTGGTATGGGGGAGAGGGTA-3’, antisense: 5-GGATTTATTTA- 
GAGAGGAGG-3’). Nested PCR amplification was similarly carried out by 
using 0.5ml of the first PCR reaction mixture as a template (sense: 5’- 
GAGAGGGTATAGGGTTAGAT-3’, antisense: 5’-AGTGAAGAGGATTTATTTAG-3’).
Agarose gel-purified PCR products were directly sequenced using a 
sequencing kit (Sequencing PRO, TOYOBO, Osaka, Japan) with primers 
radiolabelled with [¡-32P] ATP. Methylation status was investigated at 
seven CpG sites in the MN/CA9 5’ region (Fig. 1).
72
Methylation of G250 gene in vitro
146 AGCTTTGGTA TGGGGGAGAG GGCACAGGGC CAGACAAACC TGTGAGACTT TGGC|TCCATCj
Inr
-86 TC T g c a a a a g  g g c g c t c t g |t  g a g t c a G]c c t  g c t c c c c t c c  A g g c t t g c t C Ic t c c c c c a c C  
1 A P1 4 p53 AP2
-26 gAGCTCTCGT t t c c a a t g c a  c g t a c a *g c c c  g t a c a c a c c g  t g t g c t g g g a  c a c c c c a c a g  
2 3 4 5
+35 t c a g c c g c At  *g g c a c c c c t g  t g c c c c a g c c  c c t g g c t c c c  t c t g t t g a t c  c c g g c c c c t g  
6 7
-95 CTCCAGGCCT CACTGTGCAA CTGCTGCTGT CACTGCTGCT TCTGGTGCCT GTCCATCCCC
Figure 1. The 5’ region of the human MN/CA9 gene. The methylation status 
of numbered CpGs was examined in the present study. Consensus sequences 
for initiator (Inr) and transcription factors (AP1, AP2 and p53) are surrounded 
with boxes. The asterisk indicates the transcription start site. Three dots 
indicate the translation start site.
R ESU LT S
MN/CA9 expression
RT-PCR revealed five of seven human RCC cell lines (SKRC-01, SKRC- 
06, SKRC-10, SKRC-44 and SKRC-59) showed expression of 495-bp 
transcripts (Fig. 2). Confirmation of identity as MN/CA9 cDNA was 
undertaken by cloning and subsequent sequencing of the SKRC-44 
positive band. No evidence of MN /CA9 expression was detected in the 
other two RCC cell lines (SKRC-12 and SKRC-14) or in three normal 
kidney tissue samples.
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RCC (SK R C ) Normal
M 01 06 10 12 14 44 59 1 2 3 H2O
Figure 2. Differences in MN/CA9 expression among seven human RCC cell 
lines (SKRC-01, SKRC-06, SKRC-10, SKRC-12, SKRC-14, SKRC-44, and 
SKRC-59) and three normal kidney tissue samples as demonstrated by RT-PCR.
The arrow indicates 495 bp MN/CA9 transcripts. MN/CA9 expression was 
observed in SKRC-01, SKRC-06, SKRC-10, SKRC-44, and SKRC-59 but not in 
SKRC-12, SKRC-14 and all normal kidney tissue samples. H2O, negative 
control without cDNA; M, size markers.
CpG methylation status of the MN/CA9 gene
The region immediately upstream of the transcription start site of the 
MN/CA9 gene has no TATA box and no CpG island, and contains 
consensus sequences for transcription factors such as AP1, AP2 and p53
[3]. This region has been demonstrated to have promoter activity [19]. 
Unmethylated cytosines are amplified as thymines with the bisulfite 
genomic sequencing protocol and only methylated cytosines are amplified 
as cytosines [18]. Table 1 shows results for the methylation status of the 
MN/CA9 gene in RCC cell lines and normal kidney tissue samples. All 
seven CpG sites were methylated in three normal kidney tissue samples 
and two RCC cell lines (SKRC-12 and SKRC-14), while no CpG site was 
methylated in three RCC cell lines (SKRC-01, SKRC-10 and SKRC-44). 
About one half of examined CpG sites were unmethylated in each of the
74
Méthylation of G250 gene in vitro
other two RCC cell lines (SKRC-06 and SKRC-59). Partial méthylation, 
pointing to the existence of both methylated and unmethylated cytosines, 
was observed for SKRC-6 and SKRC-59. Fig. 3 shows bisufite genomic 
sequences of SKRC-14 and SKRC-44.
Figure 3. Methylation map around the transcription start site of the 
MN/CA9 gene. Arrow heads indicate methylated cytosines in SKRC-14 and 
thymidines converted from unmethylated cytosines in SKRC-44 at four CpG 
sites (CpG2, 3, 4 and 5 in Figure 1). Cytosines that are not associated with CpG 
were all converted to thymidines in both SKRC-14 and SKRC-44. The asterisk 
indicates the transcription start site.
Correlation between MN/CA9 expression and hypomethylation 
In MN/CA9 expressing cell lines, the 5’ region was hypomethylated, while 
non-MN/CA9 expressing tissues and cell lines showed hypermethylation of 
this region (Table 1).
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Table 1. Methylation status and expression of the MN/CA9 gene
___________ CpG sites*___________
o i -t o o c o v MN/CA9 Samples 1 2 3 4 5 6 7 ________ _______________________________________________ expression
SKRC-01 ............................................. ................. Yes
SKRC-06 - - - + - ± + Yes
SKRC-10 ............................................. ................. Yes
SKRC-12 + + + + + + + No
SKRC-14 + + + + + + + No
SKRC-44 ............................................. ................. Yes
SKRC-59 - - ± - - + + Yes
Normal 1 + + + + + + + No
Normal 2 + + + + + + + No
Normal 3______ + + + + + + +___________ No_________
*+ : methylated, - : unmethylated, ± : partially methylated
Induction of MN/CA9 expression by 5-aza-2’-deoxycytidine treatment
We examined whether treatment with a demethylating agent, 5-aza-2’-
deoxycytidine induces MN/CA9 expression in MN/CA9-negative RCC cell
lines. Products of 309 bp by nested RT-PCR amplifications were detected
with SKRC-14 treated for 3 d and with both SKRC-12 and SKRC-14 treated
for 7 d (Fig. 4). A positive band of 495 bp was not detected by first PCR
amplifications in any of the RCC cell lines treated with 5-aza-2’-
deoxycytidine. Table 2 shows the methylation status of MN/CA9 5’ region in
SKRC-12 and SKRC-14 treated for 7 d. Demethylation was observed at
two and four CpG sites in SKRC-12 and SKRC-14, respectively.
Table 2. Methylation status of the MN/CA9 gene after 5-aza-2’- 
deoxycytidine treatment
CpG sites1-
Samples______________1 2 3 4 5 6 7
SKRC-12 + + + + - +
SKRC-14_____________- + - + +
*Samples were treated with 5-aza-2’-deoxycytidine for 7 days. 
f+  : methylated, - : unmethylated
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SKRC-12 SKRC-14
M 1 2 3 4 5 6 H2O
Figure 4. Induction of MN/CA9 expression in MN/CA9 negative RCC cell lines 
treated with 5-aza-2’-deoxycytidine. The arrow indicates 309 bp MN/CA9
transcripts revealed by nested RT-PCR. MN/CA9 expression was induced in SKRC- 
12 treated for three days and in SKRC-14 treated for seven days. Lanesl and 4: 
without treatment, Lanes 2 and 5: three days treatment, Lanes 3 and 6: seven days 
treatment. H2O: negative control without cDNA, M: size markers.
DISCUSSIO N
The present finding of a strong correlation between hypomethylation of the 
5’ region and MN/CA9 gene expression provides evidence that the MN/CA9 
promoter may be inactive when methylated and requires hypomethylation 
to start transcription. Hypomethylation in the region immediately upstream 
and downstream of the transcription start site may be more important for 
MN/CA9 expression, since the first five CpG sites examined were highly 
unmethylated in MN/CA9 positive cell lines. DNA binding of several 
transcription factors whose recognition sequences contain a CpG are 
directly inhibited when the CpG is methylated [14]. Since no CpG has been 
found within the potential binding sites for transcription factors in the
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MN/CA9 promoter region, CpG methylation may repress the transcription 
indirectly by modulation of chromatin structure [20]. This hypothesis is 
supported by the recent report that MeCP2 binding to methylated DNA 
recruits histone deacethylase to promoters and causes chromatin assembly
[21].
A critical role of DNA hypomethylation for MN/CA9 expression in 
RCCs was confirmed by the present finding that 5-aza-2’-deoxycytidine 
treatment activated the MN/CA9 gene in MN/CA9 negative RCC cell lines. 
It is well established that 5-aza-2’-deoxycytidine, which inhibits DNA 
methylation, can reactivate genes silenced by hypermethylation [22, 23]. In 
RCC cell lines expressing MN/CA9 constitutively, its expression could be 
demonstrated by the convenional RT-PCR, whereas in negative cell lines 
under these conditions (SKRC-12 and SKRC-14) a nested RT-PCR was 
needed to detect MN/CA9 expression induced by 5-aza-2’-deoxycytidine 
treatment. This indicates that the expression levels of MN/CA9 in treated 
cell lines were much lower compared to those expressing constitutively. 
The explanation for this result may be that demethylation was insufficient to 
activate the MN/CA9 gene in treated cell lines. In fact, the first five CpG 
sites were less frequently demethylated in these cell lines. Another 
explanation is that other factor(s) might be involved in MN/CA9 expression 
in conjunction with hypomethylation. Recently, Ivanov et al. have reported 
that MN/CA9 expression was strongly inhibited by reintroduced wild-type 
VHL in an RCC cell line with a VHL mutation [24]. Their data suggest that
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the MN/CA9 gene may be one of the targets of VHL and may be activated 
by VHL dysfunction. Further examination is necessary to reveal the 
relationship between MN/CA9 hypomethylation and VHL dysfunction in 
MN/CA9 expression in RCCs.
Among other tissue specific carbonic anhydrase (CA) genes, the 
methylation status has been examined for the CA1 and CA3 genes, which 
encode products characteristic of erythrocytes and red skeletal muscle, 
respectively [25, 26]. It has been revealed that a region near the promoter 
is hypomethylated in these genes, irrespective of the expression status [25, 
26]. Other regulatory mechanisms, such as tissue specific transcription 
factors and post transcriptional regulation, may act with these genes.
The present study revealed that MN/CA9 expression was related to 
hypomethylation of the 5’ region in RCC cell lines. We are currently 
investigating the correlation between hypomethylation and expression of 
the MN/CA9 gene by using RCC tissue samples. In our preliminary study, 
hypomethylation of this gene was certainly observed in several RCC tissue 
samples expressing MN (data not shown). Therefore, we believe that the 
presently described results were not the consequences of maintenance of 
the lines in cell culture. In conclusion, our findings suggest that 
hypomethylation of 5’ region may largely contribute to expression of the 
MN/CA9 gene in RCC cells.
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Methylation of G250 gene in vivo
ABSTRACT
Objectives. In renal cell carcinoma (RCC) cell lines expression of the 
RCC-associated antigen G250 correlates with hypomethylation of the 
investigated CpG dinucleotides in the G250 promoter region, despite the 
absence of a CpG island. To gain insight into the molecular mechanism 
leading to G250 expression in vivo, we ascertained whether this correlation 
between G250 gene expression and the methylation status of the G250 
gene also existed in primary RCC and normal kidney tissue.
Methods. G250 mRNA and protein expression was determined by RT- 
PCR, FACS analysis and immunohistochemistry in 15 RCC cell lines and 
13 paired primary RCC/normal kidney tissue specimens. The methylation 
status of the G250 gene was determined by bisulfite genomic sequencing. 
Results. RCC cell lines revealed a clear correlation between G250 
expression and hypomethylation. In contrast, no hypomethylation was 
observed in primary RCC compared with normal kidney tissue. Actually, 
CpG dinucleotides investigated were generally completely methylated in 
RCC as well as normal kidney tissue. Furthermore, a primary culture of 
RCC tissue revealed increasing hypomethylation of the G250 gene in 
successive passages, suggesting that the G250 hypomethylation observed 
in vitro is tissue culture induced.
Conclusions. The methylation status of the G250 gene is correlated with 
G250 expression in vitro but not in vivo.
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INTRODUCTION
Methylation of CpG dinucleotides within gene promoter regions has been 
established as an important regulatory mechanism for gene expression. In 
tumor cells changes in the methylation patterns of the genome have been 
observed including global hypomethylation and regional hypermethylation, 
which may lead to aberrant, increased or decreased gene expression1. 
E.g., DNA hypermethylation of CpG-rich promoter regions (CpG islands) is 
an important mechanism for the inactivation of tumor suppressor genes1.
We have previously shown that in renal cell carcinoma (RCC) cell 
lines expression of the RCC-associated antigen G250 is associated with 
hypomethylation of the G250 promoter region2. This antigen is expressed in 
>80% of primary and metastatic RCC, and not expressed in normal kidney 
tissue3,4. A strict correlation between G250 mRNA and protein expression 
indicated that G250 expression is predominantly regulated at the 
transcriptional level3. Although the G250 promoter region does not contain 
a CpG island, it appeared to be regulated by the methylation status of the 
CpG dinucleotides tested in cell lines. In view of these observations we 
have studied paired RCC/ normal kidney specimens to investigate whether 
in vivo hypo-methylation of the G250 gene can explain its aberrant 
expression in RCC cells.
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MATERIAL AND METHODS
Cell lines, FACS analysis and Immunohistochemistry 
Cell lines were maintained in RPMI 1640 supplemented with 10% fetal calf 
serum and glutamine (Life Technologies, Breda, The Netherlands). G250 
protein expression was tested by FACS analysis as described3 Samples 
were investigated on a Coulter Epics flowcytometer (Beckman Coulter Inc., 
Fullerton, CA). Immunohistochemical analysis of G250 expression was 
performed on cryostat sections as described previously4.
RT-PCR
RNA from cell lines was extracted using TRIzol® extraction according to the 
manufacturer’s instructions (Life Technologies). RNA from primary tissues 
was isolated using lithium chloride/ urea extraction5. The RNA was treated 
with RNAse free DNAse (amplification grade, Life Technologies) according 
to the manufacturer’s instructions, whereafter cDNA was synthesized using 
SUPERSCRIPT™!! RNAse H- reverse transcriptase (Life Technologies).
PCR reactions were performed with intron spanning primers (Life 
Technologies): sense CTAAGCAGCTCCACACCCTCT and antisense 
TCTCATCTGCACAAGGAACG for the 251 bp G250 product and sense 
AGCAGAGAATGGAAAGTCAAA and antisense TGTTGATGTTGGATAAGAGAA for 
the 535bp p2-microglobulin product. PCR reactions were performed in 25ml 
containing 1x PCR buffer (1.5mM MgCl2, HT Biotechnologies LTD,
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Cambridge, United Kingdom), 0.1 mM of each dNTP, 0.5pmol of each 
primer and 0.5U Supertaq DNA polymerase (HT Biotechnologies LTD). 
MgCl2 was added to a final concentration of 3.5mM MgCl2 for G250 
amplification and to 2.0mM MgCl2 for p2-microglobulin amplification. The 
samples for G250 amplification were subjected to 35 cycles 94°C for 1min, 
60°C for 1min, 72°C for 1min and the samples for p2-microglobulin 
amplification were subjected to 25 cycles 94°C for 1min, 58°C for 1min, 
72°C for 1min. Reaction mixtures were analyzed on agarose gel.
DNA isolation and bisulfite genomic sequencing
Genomic DNA was prepared according to Sambrook et al. 6. To determine 
the CpG methylation status bisulfite genomic sequencing was performed as 
described previously2. In short, 2mg genomic DNA was digested with 50U 
EcoRI (Amersham Pharmacia Biotech, Roosendaal, The Netherlands), 
purified with phenol-chloroform-isoamyl alcohol and resuspended in 40ml 
TE buffer (10mM Tris-HCl pH8.0; 1mM EDTA). The DNA was denatured by 
adding freshly prepared NaOH to a final concentration of 0.3M and 
incubation for 15 min at 37°C. For the deamination reaction the DNA was 
incubated with freshly prepared 5.36M urea/3.44M bisulfite/
0.5mM hydroquinone pH5.0 under mineral oil and subjected to 20 cycles 
55°C for 15 min/95°C for 30 s followed by 55°C for 16hr. To desalt the DNA 
Wizard® DNA clean up resin was used (Promega Benelux, Leiden, The 
Netherlands). PCR primers designed for the bisulfite treated DNA were
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used for first (sense 5'TTGGTATGGGGGAGAGGGTA3' and antisense 
5'CCTCCTCTCTAAATAAATCC3') and nested (sense 5'GAGAGGGTATAGGGTT 
AGAT3' and antisense 5'AGTGAAGAGGATTTATTTAG3') PCR reactions2. PCR 
products were sequenced with the ABI PRISM BigDye Terminator Cycle 
Sequencing kit (PE-Biosystems, Nieuwerkerk a/d ljssel, The Netherlands) 
on an automated DNA Analyzer (ABI PRISM 3700, PE-Biosystems).
RESULTS
G250 protein and mRNA expression
Cell lines: G250 protein expression was determined by FACS analysis 
(Table 1). Six RCC cell lines showed strong, homogeneous fluorescent 
staining intensity indicating high G250 protein expression. The other 9 RCC 
cell lines were G250 antigen negative.
To assess G250 mRNA expression, the cell lines were evaluated by 
RT-PCR (Table 1). For all six G250 protein-positive cell lines the expected 
G250-specific product was amplified. In seven G250 protein-negative cell 
lines, no G250-specific product could be amplified. Extremely low G250 
mRNA levels were observed in SK-RC-33 and SK-RC-26B. However, G250 
Northern blot analysis was completely negative (data not shown). 
Additionally, these cell lines were negative for G250 protein by FACS 
analysis, suggesting that these low mRNA levels may not be physiologically 
relevant.
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Table 1. Méthylation status and expression of the G250 gene in
RCC cell lines
G250+ G250-
cell line
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w
002-OQ1*
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0co-o
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w
5co-O
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ooco-O
ce
w
25-o
ce
w
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s o o T - ^ r n o i n o i r n
------------------------------------------o o o o o o o o o
c e c e c e c e c e c e c e c e c e
i D i D i D i D i D i D i D i D U )
G250 protein (%) 95 95 95 95 95 95 0 0 0 0 0 0 0 0 0
G250 mRNAf 
P2M mRNA
CpG sitesi
1 0 0 0 0 0 ND§ • • • • • • O • •
2 0 0 0 0 0 O O • O • • • O O •
3 0 0 0 0 0 O O • • • • • O O •
4 0 0 0 0 0 O O • • • • • O O •
5 0 0 0 0 0 O O • O • O • O O •
6 0 0 0 0 0 O O • O • • O O O O
7 0 0 0 0 0 O • • O • • • O O •
8 0 0 0 0 0 O • • O O • • O • •
9 0 0 0 0 0 O O • O • • O O O •
determined by FACS analysis 
t determined by RT-PCR, b2M: p2-microglobulin
J • :  methylated, ® : partially methylated, o : unmethylated CpG dinucleotide 
§ ND: not determined
Primary RCC/ normal kidney: G250 protein expression was determined on 
cryostat sections of paired RCC/ normal kidney tissues by 
immunohistochemistry with mAb G250 (Table 2). In agreement with our 
earlier results, all clear cell type RCC showed homogeneous, intense G250 
expression4, whereas RCC of the papillary/ chromophilic (sample 1) and of 
the chromophobic subtype (sample 11) were G250-negative (Table 2). 
Adjacent normal kidney tissue never expressed the G250 protein.
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Table 2. Methylation Status And Expression Of The G250 
Gene In Primary RCC And Normal Kidney Tissues
sample
tissue*
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9
T: renal cell carcinoma; N: normal kidney 
t as determined by immunohistochemistry. 100% and 0% indicate all respectively none 
of RCC cells were G250 positively stained. Sample 1: papillary/chromophilic RCC; 
sample 11: chromophobic RCC; all other samples: clear cell RCC 
J as determined by RT-PCR; p2M: p2-microglobulin 
f ND: not determined 
§
$ .
•  : methylated, ® :partially methylated, o :unmethylated CpG dinucleotide
: different methylation pattern between RCC and normal kidney
G250 mRNA expression of the paired RCC/ normal kidney samples 
was also assessed by RT-PCR (Table 2). G250 specific mRNA was 
demonstrated in all immunohistochemical G250 positive RCC samples. In 
immunohistochemical G250 negative RCC no G250 mRNA could be 
detected (sample 1 and 11). In most normal kidney samples a faint signal 
was observed, possibly due to contaminating tumor cells.
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Primary RCC culture: FACS analysis of G250 protein expression in 
successive passages showed a decrease of G250 expression from 50% at 
passage 1 to 9% at passage 7 (Table 3). Immunohistochemical staining of 
the cells with CK18-2, a marker for epithelial cells7, showed positive 
staining (>90%), indicating that the culture predominantly contained RCC 
cells. In all passages G250 mRNA expression was detected by RT-PCR 
(Table 3).
Table 3. Methylation status and expression of 
the G250 gene in primary RCC cell line
G250 protein* 
G250 mRNA1' 
feM mRNA
CpG sites*
eus
siit
C
C
R
egassap
3
egassap
5
egassap
7
egassap
+ 50% 13.5% 9.5% 9.0%
1 •  © © © ©
2 •  © © © ©
3 •  • © © ©
4 •  • © © •
5 •  • o o o
6 •  • © o o
7 •  • © © ©
8 •  • © o ©
9 •  • © © ND§
* determined by immunohistochemistry (RCC tissue) and FACS 
analysis (primary culture)
1 determined by RT-PCR of RCC tissue and passages 2,4,6 and 8 
of primary culture; b2M: b2-microglobulin
* • :  methylated; ©:partially methylated; o :unmethylated CpG 
dinucleotide
§ ND: not determined
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Méthylation status G250 gene
Cell lines: The methylation status of 6 CpG dinucleotides present in the 
promoter and 3 CpG dinucleotides in exon 1 of the G250 gene was 
determined (Fig. 1). In all 6 RCC cell lines exhibiting high G250 expression 
CpG dinucleotides nr 1-8 were completely unmethylated and site nr 9 was 
unmethylated in 5/6 cell lines (Table 1).
AGCTTTGGTA TGGGGGAGAG GGCACAGGGC CAGACAAACC TGTGAGACTT TGGCTCCATC 
1
TCTGCAAAAG GGCGCTCTGT GAGTCAGCCT GCTCCCCTCC AGGCTTGCTC CTCCCCCACC
2 3 4 I 5 *
CAGCTCTCGT TTCCAATGCA CGTACAGCCC GTACACACCG TGTGCTGGGA CACCCCACAG
7
CTCCCCTG TGCCCCAGCC CCTGGCTCCC TCTGTTGATC CCGGCCCCTGTCAGCCGC AT G
CTCCAGGCCT CACTGTGCAA CTGCTGCTGT CACTGCTGCT TCTGa / gTGCCT GTCCATCCCC
8
AGAGGTTGCC CCGGATGCAG GAGGATTCCC CCTTGGGAGG AGGCTCTTCT GGGGAAGATG
9
ACCCACTGGG CGAGGAGGAT CTGCCCAGTG AAGAGGATTC ACCCAGAGAG GAGGATCCAC
Figure 1. 5’ region of the G250/MN/CAIX gene. Arrow: transcription start site3; 
box: translation start ATG; CpG dinucleotides investigated are underlined.
In contrast, in 9 G250-negative RCC cell lines all investigated CpG 
dinucleotides were partially or completely methylated in the majority of the 
cell lines (Table 1). Unmethylated CpG dinucleotides were infrequently 
observed, without a consistent pattern.
Primary RCC/ normal kidney: Since CpG methylation and G250 gene 
expression appeared to be correlated in RCC cell lines, we examined the 
methylation status of these CpG dinucleotides in paired RCC/normal kidney
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specimens. In 5/11 G250-positive RCC the methylation patterns of the 
tumor tissue and normal kidney tissue were identical, with complete 
methylation occurring in the majority of CpG dinucleotides examined 
(Table 2). For the remaining 6 G250-positive tumors studied, slight 
differences were observed between RCC and normal kidney tissue at 
maximal 5 CpG dinucleotides per specimen. This concerned hypo- as well 
as hypermethylation of the RCC specimen in comparison to the normal 
kidney tissue. Consistent hypomethylation of a (unique) CpG dinucleotide 
in RCC DNA compared with normal kidney DNA was not observed.
In 2 RCC/ normal kidney specimens no G250 expression was 
detected by immunohistochemistry. The methylation pattern of one G250- 
negative RCC was identical to the normal kidney counterpart, whereas 
differential methylation of three CpG dinucleotides was observed for the 
second G250-negative RCC examined (Table 2).
Primary RCC culture: In view of the dramatic difference between the 
G250 methylation status of RCC/ normal kidney tissues and RCC cell lines, 
we wondered whether in vitro passage of RCC tissue lead to similar 
methylation patterns. In the primary RCC tissue all 9 CpG dinucleotides 
were completely methylated (Table 3). In the first passage of the primary 
culture hypomethylation occurred in 2/9 CpG dinucleotides. At the same 
time, only 50% of cells were G250-positive by FACS analysis.
In successive passages additional hypomethylation was observed. 
FACS analysis of these cultures revealed further decrease in G250 protein
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expression to 9% at passage 7. This contrasts strongly with the complete 
hypermethylation observed in G250-negative RCC cell lines.
DISCUSSION
In a previous study we have shown that hypomethylation of CpG 
dinucleotides in the G250 gene correlated with expression of the G250 
antigen in 7 RCC cell lines2. In RCC cell lines natively expressing the G250 
gene product the investigated G250 promoter region was always non- or 
hypo-methylated in comparison to G250-negative RCC cell lines that 
showed complete methylation of this region. Additionally, 5-aza-2’- 
deoxycytidine treatment resulted in induction of G250 expression, albeit 
that nested PCR was necessary to visualize the G250 mRNA, raising 
questions as to whether this low mRNA level resulted in relevant G250 
protein levels. Furthermore, the CpG dinucleotides were not contained 
within a CpG island, also raising questions to the importance of these 
qualitative differences. We have extended our in vitro observations with 15 
RCC cell lines and studied the significance of G250 promoter methylation in 
vivo in 13 paired RCC/ normal kidney tissue specimens.
RCC cell lines expressing high levels of G250 revealed an almost 
completely unmethylated promoter region. In G250-negative RCC cell lines 
distinct methylation was seen, but unmethylated CpG dinucleotides were 
also observed, albeit infrequently, similar to our earlier report2. Collectively,
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these results suggest a correlation between methylation status and G250 
expression in RCC cell lines: an almost completely unmethylated promoter 
region appears necessary for high G250 RNA and protein levels. It 
suggests that individual CpG dinucleotides can regulate G250 gene 
transcription, similar to regulation of the human L-histidine decarboxylase 
gene8. Obviously, methylation of all CpG dinucleotides is not necessary to 
repress G250 gene expression. This has previously been observed for e.g., 
the human p16, O6-methylguanine-DNA methyltransferase and mouse c­
fos genes9,10,11.
Paired RCC/ normal kidney specimens did not show a consistent 
difference in methylation of the CpG dinucleotides tested. In general, the 
investigated region was partially or completely methylated, irrespective of 
G250 expression. The difference between the RCC cell lines and primary 
RCC tissues is striking: in primary RCC tissues methylation is typically 
complete, whereas in the majority of RCC derived G250-positive cell lines 
this promoter region is profoundly unmethylated. Thus in vivo, methylation 
of the G250 gene is not involved in regulation of expression of G250, 
whereas it may play a role in RCC cell lines. This is in agreement with a 
limited number of studies showing that methylation and gene expression
12 13 14 15
are not related in vivo, whereas a correlation exists in vitro1’ ’ ’ . In most 
studies gene expression and in vivo and in vitro methylation do 
correlate16,17,18.
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In vitro culture of RCC tissue lead to immediate hypo-methylation of 
the G250 promoter region, as described for a variety of other tissue-specific 
genes. In general, in vitro culture induces alterations in DNA 
methylation13,14,19, i.e., rapid hypomethylation of promoter regions in primary 
tissue cultures19, followed by partial remethylation once these cultures 
immortalize13,19,20. G250 hypomethylation in short-term culture was 
accompanied by loss of G250 expression, whereas the reverse was seen in 
established RCC cell lines. However, immortalization of this short-term 
culture might have lead to remethylation (see above), resulting in a G250- 
negative RCC cell line. Alternatively, selection of a subpopulation of G250- 
positive, hypomethylated cells could eventually give rise to a G250-positive 
cell line. Currently we cannot exclude either possibility.
Despite CpG methylation of the G250 promoter in primary RCC 
tissues, the G250 gene is expressed at high levels. Several investigators 
have shown that methylation of promoter regions does not necessarily 
prevent transcription and gene expression21,22,23. Obviously, transcription 
factors necessary for G250 transcription can bind to the methylated 
promoter region and activate transcription.
CONCLUSIONS
In RCC cell lines hypomethylation of CpG dinucleotides in the G250 gene 
correlated with expression of the G250 antigen. Strikingly, in paired RCC/
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normal kidney specimens the investigated region was partially or 
completely methylated, irrespective of G250 expression, i.e., no correlation 
between gene expression and methylation status was observed. In 
conclusion, it appears that in vivo G250 gene expression is not regulated 
through differential methylation, but possibly through other regulatory 
mechanisms.
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SP1 and HIF essential for G250 expression
ABSTRACT
Renal cell carcinoma of the clear cell type (ccRCC) is associated with loss 
of functional Von Hippel-Lindau (VHL) protein and high expression of the 
G250caix/mn (G250) protein. This high expression of G250 is found in all 
ccRCCs, and only in a few cell types of the gastrointestinal tract. Therefore, 
the G250 promoter is an interesting tool to be used for the treatment of 
RCC. In order to identify the promoter elements that are responsible for the 
RCC-specific expression of the G250 gene, we have isolated and 
characterized its promoter. Sequence analysis of the G250 5’-flanking region 
was performed and several promoter-reporter constructs were prepared, 
which were transiently transfected in G250-positive and negative cell lines. 
We found that most G250 promoter constructs display strong promoter 
activity in G250-positive cells, but no activity in G250-negative cells. 
Mutations of the Sp1 binding element (-50/-41) or the HIF binding element 
(-18/-13) completely abolish G250 promoter activity, indicating that these 
factors are critically important for the activation of G250 expression. 
DNase-I footprint and band-shift analysis show that Sp1 and HIF-alpha 
proteins, in nuclear extracts of RCC cells, bind to these elements in the 
G250 promoter, emphasizing their role in G250 regulation. Cotransfection 
experiments using E1A and E1A mutants deficient in CBP/p300 interaction 
indicate that the cofactor CBP/p300 participates in the regulation of G250 
transcription. In conclusion, a transcription factor complex consisting of at
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least HIF-1, Sp1 and CBP/p300 regulates the expression of G250 in 
ccRCC.
INTRODUCTION
G250caix/mn (G250) protein, a member of the carbonic anhydrase family, 
has been implicated as a possible marker for hypoxia, a prognostic factor in 
patients with advanced Renal Cell Carcinoma (RCC), and may be involved 
in oncogenesis and tumor progression of non-RCC tumors (1-3). 
Constitutive, heterogeneous G250 expression has been shown in various 
tumor types with absence of G250 expression in the corresponding normal 
tissue. Immunohistochemical studies of malignant kidney tissue 
consistently demonstrated high, homogeneous G250 expression in clear 
cell Renal Cell Carcinoma (ccRCC), suggesting that critical elements 
promoting G250 expression are constitutively present/active in ccRCC.
Somatic inactivation of the Von Hippel-Lindau (VHL) gene is 
common in sporadic ccRCC and is considered as an important initiating 
event (4-6). The VHL gene contains two open reading frames, with both 
proteins retaining tumor suppressor activity (7). This protein functions as an 
E3 ubiquitinase for several proteins including the hypoxia-inducible 
transcription factor-alpha subunits (HIFa). The involvement of transcription 
factors HIF-1 and HIF-2 in G250 transcription has been recognized (8), but 
in other studies overexpression of HIF-1a could not be detected in a
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substantial subpopulation of RCC (9), suggestive of other control elements 
in G250 promoter activation.
In addition to HIF, several critical promoter regions have been 
identified in HeLa cells, harboring AP1 and Sp1 binding sites (10). The 
precise role of these and the HIF factors in the cooperative activation of the 
G250 promoter in RCC remain unclear. To further understand the 
transcription factor complex governing G250 promoter activation in RCC we 
performed a detailed analysis of the G250 promoter in RCC cells.
MATERIALS AND METHODS 
Isolation of the G250 promoter
G250 genomic sequences were isolated from a 1FIXII human placenta 
genomic DNA library (Stratagene) as described (11). A G250 cDNA 
fragment (pMW3, basepairs 23 to 256) was radiolabeled and used as probe 
for the hybridizations. DNA was isolated from phage EO6 according to 
Sambrook et al. (12), digested with several restriction enzymes and 
subcloned in pBluescript or pUC18 plasmid vectors. Plasmid DNA was 
isolated by standard procedures (12) and sequenced using vector-specific 
primers, the ABI PRISM BigDye Terminator Cycle Sequencing kit (PE- 
Biosystems) and an automated DNA Analyzer (ABI PRISM 3700, PE- 
Biosystems).
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Promoter Reporter plasmid construction
A 1.1 kb Acil fragment of pEO6.5.1 (-1068/+31) was blunt-ended by T4- 
DNA polymerase and ligated by T4-ligase into the Hincll site of the 
promoter-less reporter plasmid p0GH (Nichols Diagnostics Institute). 
Truncation of the reporter plasmid was performed by PCR amplification of 
the regions of interest using pEO6.5.1 as a template and the following 
H/'ncll-tagged forward primers and a Xbal-tagged reverse primer (tags not 
shown): 5’-CCCATTACTTAACTCACCC-3’ (-479/-461); 5’-GCCAGGTGGTGCCTT- 
GGG-3’ (-247/-230); 5’-GCACACACCTGCCCCT CAC-3’ (-189/-171); 5’- 
T GT GAGACTTT GGCTCCA-3’ (-116/-99); 5’-GCAAAAGGGCGCTCTGTG-3’ 
(-93/-76); 5’-CTCCAGGCTTGCTCCTCC-3’ (-60/-43); 5’-CTCGTTTCCAATGCACGT- 
3’ (-31/-14); 5’-ACCGTGTGCTGGGACACC-3’ (+1/+18); and 5’- 
CGGCTGACTGTGG-3’ (+31/+19). PCR products were digested with 
Hincll/Xbal, gel-purified and cloned into the Hincll/Xbal sites of p0GH. The 
pTKGH plasmid, containing the Herpes Simplex Virus-thymidine kinase 
(HSV-tk) gene promoter (Nichols Diagnostics Institute), was used as 
positive control in the transient transfection assays. To correct for 
transfection efficiency the b-galactosidase expression plasmid pCMV-110 
was co-transfected with the promoter-reporter constructs. Adenovirus E1A 
gene constructs were kindly provided by Dr. A. Zantema (Mol. Cell Biol., 
Leiden Univ. Med. Center, Leiden, Netherlands) (13). Constructs were 
digested with Hindlll/Sacl, gel purified and cloned into pUC18.
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Site directed mutagenesis was performed using the GeneEditor in 
vitro site-directed mutagenesis system, according to the manufacturers’ 
instructions (Promega). The "mutagenic” oligonucleotides used were, in 
forward orientation: 5’-AACCTGTGACACTTTGGC-3’ (mutation of the SP1/AP1- 
site at position -111) and 5’-GTCAGCCTGCTCAACTCCAGGCTTGC-3’ (Sp1-site 
at pos. -62/-61), and in reverse orientation: 5’-GGAAACGAGAGCCGGGTGG- 
GGTATTAGCAAGCCTGG-3’ (Sp1-site at pos. -43), 5’-GGAAACGAGAGCTTGGT- 
GGGGGAGGAGCAAGCCTGG-3’ (AP2-site at pos. -36), 5’-GGAAACGAGAG- 
CTGGGTGGGTGATTAGCAAGCCTGG-3’ (Sp1 and AP2-sites) and 5’- 
TACGGGCTGTACCAGCATTGGAAACG-3’ (HRE at pos. -17/-16). All constructs 
were column-purified (Qiagen) and sequenced prior to use in promoter 
assays.
Cell culture and Adenovirus infection
Human SKRC cell lines have been described previously (14). Primary 
cultures of normal kidney epithelium were grown from biopsy specimens 
taken at nephrectomy. Fresh biopsy specimens were minced using a sterile 
scalpel, resuspended in RPMI 1640 medium, and plated in 6-wells tissue 
culture plates. All cells were grown in RPMI 1640 medium, supplemented 
with 10% fetal calf serum (Gibco), in an atmosphere of 5% CO2 and 37oC.
Primary kidney epithelial cultures were infected with wildtype or 
replication-deficient adenovirus (serotype 5) at a multiplicity of infection 
(MOI) of 1.0. Three days post-infection, total RNA was isolated from the
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cultures using Trizol (Life Technologies) and analyzed by G250-specific 
RT-PCR.
Transient transfection assays
The RCC cells (SKRC-7, SKRC-10, SKRC-17 and SKRC-59) were seeded 
into 10-cm dishes at a density of 4x105 cells per dish, one day prior to 
transfection. For each transfection, 3 mg of the appropriate G250-hGH 
construct was co-transfected with 2.3 mg of pCMV-110 (encoding b- 
galactosidase) with or without E1A-encoding constructs using Fugene-6 
transfection reagent, according to the manufacturer’s instructions (Roche 
Diagnostics). All transfections were performed at least three times in duplo. 
Cells and medium were harvested 72 hours after transfection and stored at 
-20oC until use.
Human growth hormone secretion in the medium was determined 
using the two-site fluoro-immunometric Delfia hGH assay kit (Wallac Oy, 
Turku, Finland), according to the manufacturer’s instructions. hGH values 
were normalized to the b-galactosidase activities measured in the 
corresponding cell extracts. hGH values and relative induction values are 
expressed as mean and standard error of the mean (SEM).
Dnase-I footprint analysis
One strand end-labeled DNA probes were generated by first labeling the 5’ 
end of G250 promoter-specific primers with [g-32P]ATP (~3000 Ci/mmol, 
Amersham), followed by PCR amplification of DNA fragments with one
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labeled and one unlabeled primer. Labeled PCR products were purified 
from 5% polyacrylamide gels, according to Sambrook et al. (12). For each 
DNase-I footprint reaction, 1.5 to 3.0 fpu recombinant Sp1 protein 
(Promega) was used as described (15).
Electrophoretic mobility shift assay (EMSA)
Primers for PCR amplification of a G250 promoter fragment (-60/+31) and a 
double-stranded oligonucleotide, containing basepairs -8 to -27 of the G250 
promoter, were end-labeled with [g-32P]ATP (~3000 Ci/mmol, Amersham) and 
used in EMSAs (15). DNA probes (0.5 ng) were incubated with nuclear 
extracts (15 mg), and separated on 4% polyacrylamide gels as previously 
described (15). For supershift assays, antibodies against Sp1 (4mg, Santa 
Cruz), HIF-1a (2mg, Santa Cruz), HIF-2a (6.3mg, Novus Biologicals) or IgG 
control were added to the binding reactions.
RESULTS
Structure of the 5’-flanking region of the human G250 gene 
A genomic clone, 1FIX-EO6, containing the 5’ end of the human G250 
gene was identified by screening a human genomic library. DNA of 1FIX- 
EO6 was subcloned in plasmid vectors for DNA sequence analysis. One 
plasmid, pEO6.5.1 (position -1258/+260), containing exon 1 of the G250 
gene and 1.3 kb of 5’-flanking sequences was identified (Fig. 1A). The 
nucleotide sequence of the 5’-flanking region was determined (Fig. 1B).
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Figure 1. Restriction map and nucleotide sequence of the 5’-flanking region of the 
human G250 gene. (A) Restriction map of the G250 genomic clones 1FIX-EO6 and 
pEO6.5.1. (B) Nucleotide sequence of the genomic region surrounding the transcription 
start site (position 1, *) of the G250 gene. The G250 translation startcodon (ATG) is 
indicated in bold. Several potential transcription factor binding sites were identified by 
the Transcription Element Search Software (TESS) using the TRANSFAC 4.0 database 
(Schug, J. and Overton, G.C.; http//www.cbil.upenn.edu/tess) and are indicated by boxes.
Comparison of the G250 5’-flanking nucleotide sequence with 
sequences in the non-redundant nucleotide databases and the eukaryotic 
promoter database, using BLAST (16), revealed no homology to any gene, 
c.q. promoter sequences described. Identification of potential transcription 
factor (TF) binding sites by the TESS software on the WWW, using the 
TRANSFAC 4.0 matrices, revealed no canonical binding sites at consensus 
positions, i.e. no initiator element and no TATA box could be identified. 
However, several potential TF binding sites could be identified in the 
proximal promoter region (Fig. 1B), amongst which several Sp1 and AP 
elements and one hypoxia responsive element (HRE).
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Transcriptional activity of the human G250 promoter 
A 1.1 kb Aci fragment containing the putative G250 promoter (position - 
1070/+31) was cloned upstream of the human growth hormone (hGH) 
reporter gene. This construct was transiently transfected into renal cell 
carcinoma (RCC) cell lines to test whether these sequences contained 
(G250-specific) promoter activity. In the G250-positive RCC cell lines 
(SKRC-7 and SKRC-10) the 1.1 kb fragment showed strong promoter 
activity, which was 0.9 and 4-fold that of the HSV-tk promoter, respectively 
(Fig. 2A). No G250 promoter activity was observed in G250-negative RCC 
cell lines (SKRC-17 and SKRC-59). Promoters are known to function 
unidirectionally and, therefore, the 1.1 kb construct was cloned in the 
reverse orientation upstream of the hGH reporter gene. As expected, this 
construct (+31/-1070) failed to show any promoter activity (Fig. 2A).
To investigate whether regions within the 1.1 kb G250 5’-flanking 
region contributed to the G250 promoter activity, a series of 5' deletion 
constructs were generated. Transfection of the deletion constructs into 
SKRC-7 (G250-positive) cells resulted in an increased promoter activity 
(construct -479/+31), compared to the activity observed in the 1.1 kb 
construct (Fig. 2B). Further truncation of the -479/+31 construct resulted in 
a decrease (construct -229/+31) followed by another increase (constructs - 
189/+31 and -116/+31) in G250 promoter activity. When the -116/+31 
construct was further shortened, a rapid decrease in promoter activity was 
observed, although construct -60/+31 still showed significant promoter 
activity (0.6-fold of HSV-tk). As anticipated, none of the constructs tested
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showed promoter activity in the G250-negative RCC cell line SKRC-17 
(Fig. 2B). Similar results were obtained with the SKRC-10 and SKRC-52 
(G250-positive) and SKRC-59 (G250-negative) cell lines (data not shown).
A
1.0 2.0 3.0 4.0 
Relative promoter activity
B
HSV-tk
-1070/+31 ----- //
-479/+31
0.5 1.0 1.5 2.0 2.5 
Relative promoter activity
Figure 2. G250 promoter activity in the human renal cell carcinoma cell lines. (A) The
SKRC-7, 10, 17, and 59 cell lines were transiently transfected with a 1.1 kb G250 
promoter constructs in forward and reverse orientation as indicated. Positions relative to the 
transcription initiation site are indicated. Human growth hormone production in SKRC-7 
and -10 cells (G250-positive, dark resp. grey bars) and in SKRC-17 and -59 cells (G250- 
negative, cross-hatched bars) were calculated using pTKGH (hGH gene expression driven 
by the HSV-tk promoter) as a reference. Error bars indicate the standard error of the mean 
of at least three independent experiments done in duplo. (B) SKRC-7 (black bars) and 
SKRC-17 (cross-hatched bars) were also transfected with several 5’-truncated G250 
promoter constructs as indicated and analyzed as described above.
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Figure 3. Site-directed mutagenesis of the human G250 minimal promoter. (A) G250 
minimal promoter constructs (-116/+31) are indicated as lines. White boxes indicate 
positions of putative TF binding sites and black boxes indicate mutated TF binding 
sequences with numbers corresponding to their positions relative to the transcription start 
site. Promoter mutants were transiently transfected into SKRC-7 cells and hGH production 
and promoter activities were determined as described in Figure 2, using the wildtype - 
116/+31 promoter as a reference.
Site-directed mutagenesis of transcription factor binding-sites 
Several potential transcription factor binding-sites within the proximal G250 
promoter were identified (Fig. 1B). To investigate the importance of these 
factors for G250 promoter activity in RCC cell lines, several base 
substitution mutants in the -116/+31 constructs were created. Also the HRE 
was mutated since a role of hypoxia inducible factors in RCC-specific G250
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expression was suggested (8). The positions of the base substitutions are 
shown in Fig. 3. The examined mutations in the AP-1 (pos. -111) and Sp1 
(pos. -61/-62) elements or both resulted in a 50% decrease in G250 
promoter activity when compared to the wild-type -116/+31 reporter 
construct (Fig. 3). Base substitutions in the Sp1 element at position -41 to - 
50 almost completely abolished promoter activity (>95% reduction). This 
Sp1 binding site overlaps with a functional AP-2 site, shown to bind AP-2 
(10). Mutation of this AP-2 site, leaving the Sp1 site intact, did not affect 
G250 promoter activity. Finally, mutations in the HRE sequence motif (pos. 
-13/-18) also reduced promoter activity of the -116/+31 construct for more 
than 95%. These data show that the Sp1 and HRE cis-acting elements 
present in the proximal G250 promoter play a critical role in the initiation of 
G250 transcription, whereas the upstream AP-1 and Sp1 sites play a minor 
role in G250 regulation in RCC cells.
Protein-DNA interaction at the most proximal (-41 to -50) Sp1 binding site 
The presence of several functionally important Sp1 elements in the G250 
promoter prompted us to investigate the binding capacity of Sp1 protein to 
the Sp1 motifs in the G250 promoter. DNase-I footprint analysis using 
recombinant Sp1 protein and one-strand end-labeled probes, covering the 
G250 promoter, revealed the protection of two regions: -37 to -60 and -115 
to -145 (Fig. 4A). The first region corresponds to the predicted Sp1 binding 
sequence (-41 to -50; Fig. 1), whereas the second region covers the Sp1 
site at position -136 to -145, exceeding to the AP-1 site at pos. -107 to -114
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(Fig. 1). These data demonstrate that Sp1 can bind to the functionally 
critical important Sp1 site (-41/-50) within the minimal G250 promoter 
region.
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Figure 4. Binding of Sp1 to the G250 promoter. (A) DNase-I footprint analysis using 
recombinant Sp1 protein. Recombinant Sp1 protein was incubated with the end-labeled 
PCR probes and further analyzed as described in Materials &  Methods. Footprinted regions 
are indicated by vertical lines and their positions relative to the transcription start site. (B) 
EMSA using nuclear extracts of SKRC-7 (G250-positive) and SKRC-17 (G250-negative) 
and a radiolabeled oligonucleotide containing G250 sequences -60/+31. An unlabeled 
G250 fragment -60/+31 was added in 100-fold excess as competitor DNA. Sp1-specific 
antibody or an IgG1 control antibody was added as indicated. Specific protein-DNA 
complexes are indicated with black arrowheads and supershifted Sp1-containing 
complexes are indicated with an open arrowhead. Only the section of the radiographs with 
the protein-DNA complexes is shown.
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The G250 minimal promoter region (-60/+30) was used as a probe 
in electrophoretic mobility shift assays (EMSA) to study the interaction of 
Sp1 in nuclear extracts of RCC cell lines. Addition of SKRC-7 (G250- 
positive) nuclear extracts to the G250 probe, resulted in three sequence 
specific protein-DNA complexes (Fig. 4B). One of the protein-DNA 
complexes formed was supershifted, using an Sp1-specific antibody, 
whereas no such supershift was observed with an IgG1 control antibody. 
Similar results were obtained when nuclear extracts of a G250-negative cell 
line (SKRC-17) were used.
Protein-DNA interaction at the hypoxia responsive element 
The hypoxia responsive element (HRE) or putative HIF binding-site within 
the G250 promoter has been shown to be an essential element for efficient 
promoter activity in RCC (Fig. 3). To further substantiate the sequence- 
specific binding of nuclear factors to the HRE element in the G250 
promoter (pos. -13 to -18), EMSAs were performed. Three protein-DNA 
complexes were formed when NEs from SKRC-7 cells were incubated with 
an oligonucleotide containing the G250 HRE (Fig. 5). Competition 
experiment, using excess unlabeled oligos, revealed that these were 
sequence-specific protein-DNA complexes (lanes 7-9). When a functional 
VHL cDNA was ectopically expressed in the SKRC-7 cell line, the protein­
DNA interactions were completely abolished (lane 4). On the other hand, 
treatment of the cells with CoCl2 (mimicking hypoxia) resulted in an
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increased binding of the protein complexes (lanes 3, 5-6). These data 
indicate that the protein complexes are hypoxia inducible. Indeed, when 
antibodies against HIF-1a (lanes 1 and 6) or HIF-2a (lane 10) were added 
to the binding reactions, a supershift of one of the complexes could be 
observed. Interestingly, binding (and supershift) of HIF-1a to the HRE in the 
G250 promoter was only observed using NEs of G250-positive cells, 
whereas both G250-positive and negative cells produce HIF-2a capable of 
binding to the G250 HRE (data not shown).
200x competitor 
anti HIFa 
VHL 
CoCl2
< ]  HIF-2a Shift 
< ]  HIF-1 a Shift
^  HIF-1 a
^  HIF-2 a
Figure 5. DNA-binding activity to HRE within the G250 promoter. The G250-positive 
SKRC-7 cell line was stably transfected with a CMV-VHL expression construct and treated 
with 200mM CoCl2 for 24h as indicated. Subsequently, nuclear extracts were incubated with 
[32P]-labeled double-stranded oligonucleotide spanning the HIFa binding site (pos. -27 to -8) 
and analyzed by EMSA. HIF-1a and HIF-2a-specific antibodies were added to the binding 
reactions as indicated. Black arrowheads indicate the position of specific protein-DNA 
complexes, the white arrowheads, the position of HIF-1a and HIF-2a supershifted complexes 
and the arrow the position of another hypoxia inducible factor. NS, non-specific unlabeled 
competitor DNA; Sp, specific competitor. Only the section of the radiographs with the specific 
protein-DNA complexes is shown.
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Involvement of cofactor CBP/p300 in G250 transcription 
The cofactor CBP/p300 has independently been shown to bind to both Sp1 
and HIF, and hypoxic activation of HIF-1a is dependent on its interaction 
with CBP/p300 (17-20). To test whether this cofactor is involved in the 
transcriptional regulation of the G250 promoter, an E1A-encoding construct 
that can bind CBP/p300 was cotransfected with the G250 promoter 
construct -116/+31 into SKRC-10 cells. Expression of the adenovirus E1A 
gene reduced G250 promoter activity to about 25% of mock-transfected 
cells (Fig. 6A). An E1A mutant (E1ADp300), unable to bind CBP/p300, did 
not significantly alter G250 promoter activity, whereas an E1A mutant 
(E1ADRb), unable to bind Rb, but able to bind CBP/p300, also reduced 
G250 promoter activity to about 25%. These data indicate that the specific 
sequestration of p300 by E1A reduces G250 promoter activity.
In addition to the promoter studies (in vitro), the E1A gene was also 
expressed in vivo in primary kidney epithelial cell cultures by adenoviral 
infections. Wildtype adenovirus (serotype 5)-infected cells showed a more 
than 50% reduced expression of G250 compared to uninfected cells, with 
and without CoCl2 treatment (Fig. 6B and data not shown). When an E1- 
ablated adenovirus was used to infect the primary kidney cells, the G250 
expression was similar to uninfected cells. Together, these data indicate 
that indeed CBP/p300 is an important cofactor involved in the Sp1/HIF- 
mediated activation of G250 transcription.
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Figure 6. CBP/p300 involvement in G250 promoter activity. (A) The G250 
promoter construct -116/+31 was transiently co-transfected with E1A constructs as 
shown at the left into SKRC-10 cells. Promoter activity of the G250 constructs was 
determined as described in Figure 2 and was normalized to the activity of the HSV- 
tk promoter construct. (B) Primary kidney epithelial cell cultures were infected with 
wildtype adenovirus (serotype 5) or with an E1-deleted replication-deficient Ad5 
virus (MOI = 1.0). Three days post-infection, total RNA was isolated and analyzed 
by G250-specific RT-PCR. M, marker; 1 and 2, uninfected cells; 3, wildtype Ad5 
infected; 4, E1-deleted Ad5; and 5, negative control; #2-5, treated with 200 |jM CoCl2. 
b-2-microglobulin (02M) was used as a control for the quality of cDNA synthesis.
DISCUSSION
RCC of the clear cell type is associated with loss of functional Von Hippel­
Lindau (VHL) gene product and expression of the G250 protein (1-6). This 
loss of functional VHL leads to constitutive stabilization of the alpha
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subunits of hypoxia-inducible transcription factor HIF (21). Nevertheless, in 
spite of strong evidence that VHL, HIF and G250 expression are tightly 
linked (8;9;21;22), a substantial number of ccRCC do not show VHL 
aberrations and do not overexpress HIF-1 a , whereas these do express 
G250 (4;6;9). Collectively these data suggest the involvement of as yet 
unidentified transcription factors in G250 expression. Here we described 
the identification of crucial factors involved in the regulation of G250 
expression in RCC.
By sequence analysis, the minimal promoter region was shown to 
contain a putative HIF binding element and several AP-1/2 and Sp1 binding 
elements. The importance of the HIF and the most proximal Sp1 elements 
was emphasized by the dramatic decrease in promoter activity when these 
sites were mutated. Since both the Sp1 and HIF binding elements are 
essential for efficient G250 promoter activity, it is feasible that together they 
tether a coactivator (complex) to the promoter. The importance of common 
coactivator molecules for transcriptional activity is well established (23;24). 
One of these common coactivator molecules known to bind Sp1 as well as 
HIF is CBP/p300 (25;26) (cAMP responsive element binding factor (CREB)-
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binding protein). The E1A cotransfection experiments show that CBP/p300 
is indeed involved in the transcription of G250. Under hypoxic conditions 
HIF-1a can recruit the CBP/p300 cofactor independently of other 
transcription factors (18;20). This interaction involves asparagine 803 of 
HIF-1 a that is not hydroxylated under hypoxic conditions (27;28). However, 
under normoxic conditions ccRCC cells probably hydroxylate this 
asparagine impeding the signal for recruitment of CBP/p300. Under the 
latter conditions the cooperation between Sp1 and HIF may be required for 
efficient tethering of CBP/p300. Alternatively, another cofactor(s), such as 
SRC-1/p165, may be involved in G250 promoter regulation that may 
compete or cooperate with the cofactor CBP/p300 (19).
Kaluz et al. have studied the G250 promoter in the MaTu cell line, a 
lymphocytic choriomeningitis virus-infected breast tumor cell line (29;30). In 
their hands, the smallest construct tested (promoter region -183/+21) still 
contained significant promoter activity, in agreement with our results. 
However, we have shown that the minimal promoter region is substantially 
smaller. Comparison of G250 promoter analysis of these authors and our 
results revealed some dissimilarities. Kaluz et al. identified the region
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-144/-120 as repressor element binding sequence, suppressing G250 
expression in HeLa/fibroblast hybrids (10). In G250-negative 
HeLa/fibroblast hybrids, considerably more/stronger repressor binding to 
this region was observed than in G250-positive hybrid cells. In G250- 
positive and negative RCC cells, we did not observe any quantitative 
difference in binding to this element (data not shown), suggesting that in 
RCC this repressor protein is absent or does not repress G250 expression.
Additionally, In the MaTu cell line deletion of regions -55/-34 or 
-81/-66 decreased promoter activity approximately 5-fold (10). In RCC cell 
lines deletion of -93/-60 led to a 3-fold reduction of promoter activity, 
whereas deletion of -60/-33 abolished G250 promoter activity. Kaluz et al. 
have shown that AP2 is one of the transactivators binding to -55/-34. 
However, multiple complexes bind to -55/-34 as shown by EMSA (10). Our 
results suggest that binding of transactivator Sp1 and not AP-2 to this 
region determines promoter activity in RCC cells: mutation of the AP-2 
binding element did not influence G250 promoter activity, however, 
mutation of the Sp1 binding element at -43/-47 strongly diminishes G250 
promoter activity in RCC cells.
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G250 promoter activity was restricted to G250-positive RCC cell 
lines, suggesting that the G250-negative cells may lack a relevant 
transcription factor regulating G250 promoter activity. It is noteworthy to 
stress that only G250-positive RCC cells showed HIF-1a-specific binding to 
the HRE, whereas both in G250-positive and negative cells HIF-2a (and 
Sp1) binding was observed. Consequently, HIF-1a binding seems to be the 
major determinant for G250 promoter activity. However, a sizable number 
of ccRCC contain functional VHL and lack adequate amounts of HIF-1a, 
but still express G250 at high levels (see above). Therefore, in addition to 
HIF-1 a, tissue specific factor(s) may play an important role in G250 
promoter regulation. This situation is comparable to the promoter of e.g. the 
stem cell leukemia gene that is also regulated by tissue specific as well as 
general transcription factors (31). The involvement of one or more tissue 
specific factors would explain the expression of G250 in virtually all ccRCC, 
irrespective of the VHL status. In non-RCC tumors it appears that G250 
expression is tightly regulated by hypoxia and HIF protein(s) (2;3;8;32).
RCC of the clear cell type is associated with loss of functional Von 
Hippel-Lindau (VHL) gene product leading to stabilization of HIFa, which is
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associated with expression of the G250 protein. We identified the region
-60/+31 as the G250 minimal promoter region. Binding of the transcription
factors Sp1 and HIF-1 to this region of the G250 promoter is indispensable
for its activity. In addition, the cofactor CBP/p300 is recruited by Sp1 and
HIF-1 and is a major determinant of G250 promoter activity. In conclusion,
a transcription factor complex consisting of Sp1 and HIF and the cofactor
CBP/p300 strictly regulates G250 expression in RCC cells.
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General Discussion
6.1 The ccRCC-Associated Gene G250
As discussed earlier, ccRCC express a number of tumor-associated 
antigens (TAA) not expressed in normal kidney that might be involved in 
renal carcinogenesis (e.g. Oosterwijk, 1986; Vessella, 1985). One of the 
most extensively studied RCC-associated antigens concerns the antigen 
defined by mAbG250. mAbG250 carries a number of remarkable features: 
by immunohistochemistry >75% of primary and metastatic RCC express 
G250 antigen, with virtually homogenous, membranous G250 expression in 
the majority of tumors examined (Oosterwijk, 1986). Interestingly, G250 
antigen expression in normal kidney tissue, including fetal kidney tissue is 
completely absent (Oosterwijk, 1986). Although initially not recognized, all 
cells of the most prevalent subtype of RCC (ccRCC) express G250 antigen 
whereas only 50% of the other subtypes express G250 (Oosterwijk, 1995). 
Expression in normal tissues is limited to larger bile duct epithelium, 
stomach mucosal cells and cryptal cells of the ileum and colon (Oosterwijk, 
1995; Pastorekova, 1997). The G250 distribution contrasts with other RCC- 
associated antigens, which are less abundantly expressed, with no 
specificity for a defined histological RCC subtype. Collectively, this implies 
a direct, causal molecular relationship between G250 activation and 
ccRCC.
G250 antigen expression was also noted in non-RCC carcinomas, 
albeit that expression was confined to limited tumor areas, and at a much 
lower frequency (Oosterwijk, 1986). It was hypothesized that in these other 
tumor types G250 activation might also be a primary event, but it has 
become clear that this heterogeneous expression is an epiphenomenon.
Clinical trials with 131 I-labeled mAbG250 in RCC patients have 
shown that the G250 antigen can be used as a therapeutic target (Divgi, 
1998; Oosterwijk, 1993; Oosterwijk and Debruyne, 1995). In phase I/II 
clinical radiotherapy trials with 131I-mAbG250 anti-tumor responses have 
been observed (Divgi, 1998). Additionally, complete tumor regression was
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observed in animal models when a surrogate G250 antigen, in the form of 
anti-idiotype mAbs, was administered as a vaccine, suggesting that the 
antigen might serve as an immunogenic anti-tumor entity (Uemura, 1994). 
Insight into the function and molecular activation mechanism(s) of G250 
might lead to the identification of additional therapeutic target(s).
6.2 Cloning of G250
Continuing efforts to identify the G250 antigen by protein analyses using 
the mAbG250, e.g. radioimmunoprecipitation, protein purification methods 
and Western blot analyses, failed to isolate the G250 antigen. This failure 
was highly suggestive for recognition of a sterical determinant by 
mAbG250. Unfortunately, also the screening of a 1gt11 RCC-derived 
expression library failed. Eventually, the G250 cDNA was molecularly 
cloned by screening of a COS expression system with mAbG250 using 
RNA from a mAbG250-positive RCC cell line (Appendix 1). Sequence 
analysis revealed the identity with MN/CAIX (accession number Z 54349), a 
formerly described tumor-associated antigen of the cervix, not expressed in 
normal cervical cells (Appendix 1) (Pastorek, 1994; Opavsky, 1996). The 
M75 antibody recognizing MN/CAIX also detected expression of the cloned 
G250 cDNA, confirming the identity of these tumor-associated antigens 
(Appendix 1). The fact that G250 was independently cloned from a cervical 
cancer cell line and a renal cancer cell line again emphasized the possible 
role of G250 in the carcinogenesis of different tumor types.
The isolated G250 cDNA was subsequently used to isolate the 
G250 gene by screening of a human placenta genomic phage library 
(Appendix 1). The gene consists of 11 exons and introns and is highly 
conserved in different species (Opavsky, 1996). By FISH analysis using a 
genomic clone containing the 5' end of the G250 gene, the G250 gene was 
located at 9p12-13 (Appendix 1). Chromosome 9p has been implicated in 
tumor recurrence in nonmetastatic ccRCC, suggesting that loss of a tumor
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suppressor gene in this region may play a role in RCC progression (Moch, 
1996). It is highly unlikely that G250 is this tumor suppressor gene since 
LOH of chromosome 9p does not influence G250 expression: it is 
expressed in almost all ccRCC including metastasis regardless of tumor 
type, grade or stage. This is not unexpected since LOH studies are 
designed to identify putative tumor-suppressor loci, whereas G250 
expression is clearly induced upon malignant transformation, i.e., it has 
oncogene like characteristic.
6.3 Function(s) of G250
The G250 antigen is expressed in several carcinomas and not in the 
corresponding normal tissues suggesting that it may function as an 
oncogene (Oosterwijk, 1986). To test this hypothesis, the influence of G250 
expression on cell proliferation was determined. Transfection of the G250 
cDNA into G250-negative RCC cell lines did not alter the cell doubling time 
(pers. observation). More importantly, G250 cDNA transfection of primary 
proximal tubular epithelial cultures did not lead to cell immortalization 
(pers. observation). In contrast, Pastorek et al. described that transfection 
of G250 cDNA into mouse NIH3T3 cells altered several growth 
characteristics, e.g. cell doubling time, saturation density and dependence 
on growth factors, but with only small differences (Pastorek, 1994). The 
observed different results are possibly the consequence of the use of 
different cell types: NIH3T3 cells have an immortalized, nonmalignant 
phenotype. It is possible that in primary proximal tubular epithelial cultures, 
G250 activation in collaboration with other oncogenes leads to complete 
malignant transformation. Since none of currently studied oncogenes has 
shown a direct, strict correlation with RCC this must be a currently 
unidentified oncogene. Alternatively, G250 does not function as oncogene. 
Indeed, in vivo the level of G250 expression in transfected RCC cells does 
not correlate with tumor take rates, tumor growth or metastatic behavior in
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immunodeficient animals (pers. observations). Thus G250 does not 
function as an oncogene.
The predicted G250/CAIX/MN protein contains a signal peptide (aa 
1-37, exon 1), a hydrophobic transmembrane region of 20 aa (exon 10), a 
small cytoplasmic portion of 25 aa (exon 11), and a large extracellular 
portion with high homology to carbonic anhydrase VI (40.2% at the protein 
level, exon 2-8) (Appendix 1; Opavsky, 1996). The gene structure of the 
carbonic anhydrase (CA) domain of G250 is similar to other CA genes 
(Opavsky, 1996). Furthermore, most of the amino acids constituting the CA 
catalytic site are conserved in the G250 protein, particularly all zinc-binding 
histidine residues (Sly and Hu, 1995). Subsequent studies by Wingo et al., 
provided unequivocal evidence that G250/MN can function as CA (Wingo,
2001).
CAs are enzymes involved in maintenance of the acid-base balance 
by reversibly hydrating CO2 and dehydrating HCO3-, also functioning in 
CO2 transport and ion exchange (Breton, 2001; Geers and Gros, 2000; 
Henry, 1996; Sly and Hu, 1995). The extracellular location of the CA 
domain of G250 suggests a function in the maintenance of tissue/tumor 
homeostasis, particular by manipulation of the cellular (micro) environment. 
G250 is expressed in the stomach, bile ducts, colon and several tumors 
that are all tissues known to have an altered extracellular pH (Oosterwijk, 
1995;Pastorekova, 1997). This suggests that G250 might contribute to the 
extracellular acidification in these tissues. In tumors an acidic environment 
enhances invasive behavior in vitro (Martinez-Zaguilan, 1996), suggesting 
that a function of G250 in extracellular acidification might be involved in the 
carcinogenic pathway. In one renal cell carcinoma cell line induction of 
G250 RNA expression by culturing the cells to high density correlated with 
medium acidification (Ivanov, 2001). Unfortunately, evidence that G250 
protein expression and medium acidification correlated was lacking. In our 
hands, transfection of G250 into a G250-negative RCC cell line did not alter
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the pH of the culture medium, indicating that G250 might not function in 
maintenance of the extracellular acid-base balance (pers. observation). It is 
possible that the CA function of G250 regulates ion exchange and transport 
of different products (Fig. 1).
Although the presence of a proteo-glycan related sequence was 
suggested in the G250 protein (Opavsky, 1996), the G250 consensus 
repeat (EEDLPG) in exon 1 may not be functionally related to the keratan 
sulfate attachment domain of human aggrecan repeat (EEPS/FPS). The 
suggestion was based on the observation that a G250-negative HeLa- 
fibroblast hybrid can bind to purified G250 protein (Zavada, 2000). Because 
multiple proteins co-purified with the G250 protein, this adhesion might be 
explained by non-G250 specific binding (Zavada, 2000). To properly 
demonstrate that G250 functions as a cell adhesion protein, the 
identification of the G250 binding molecule is required.
Conclusively, G250 is a functional CA enzyme possibly also involved 
in cell-cell adhesion. The presence of an extracellular CA in tumor tissue is 
intriguing, because it may provide cells with a survival benefit under low 
oxygen conditions, typical for all solid tumors. For ccRCC it is unlikely that 
G250 expression is the consequence of selection and adaptation, since 
expression can be detected in very small primary ccRCC lesions (1-2 mm 
in diameter) in cadaver kidneys from elderly who died of non-ccRCC 
related causes (E.Oosterwijk, pers. observation).
Elucidation of the CA function of G250 did not explain the role in the 
carcinogenesis of several tumor types. Insight into the molecular activation 
mechanism(s) of G250 could resolve this question.
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Figure 1. Ion Exchange and Transport Regulation 
by Carbonic Anhydrase(s)
organic anion transporter
- ^ O A
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Figure 1. CAs regulate ion exchange and transport of different products.
Extracellular CAs neutralize H+ and HCO3" extruded from cells via transporters (H+ 
ATPase, monocarboxylate symporter, Na+/H+ exchanger, organic anion transporter, anion 
exchanger and Na+/HCO3" cotransporter). Furthermore, it can produce H+ and HCO3" 
required by peptide, anion, organic cation and Cl'/formate transporters, the latter depending 
indirectly on H+ through the recycling of formate via formic acid. Intracellular CAs 
maintain homeostasis through conversion of imported H+ and HCO3" to H2O and CO2.
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6.4 Mechanism(s) of Activation
Potentially, G250 might function as an oncogene activated by either by 
mutation(s) or amplification of the gene. Southern blot analysis by Pastorek 
et al., excluded gene amplification as activation mechanism (Pastorek, 
1994). Comparison of the G250 genomic and cDNA sequences did not 
show any mutation with the exception of an A/G transition in exon1 
(Appendix 1). This was shown to be a natural occurring polymorphism not 
associated with ccRCC and/or G250 expression by SSCP analysis of RCC 
and normal kidney DNA and by sequencing of G250 cDNA isolated from 
non-RCC patients (Appendix 1). Thus, the G250 gene is not mutated in 
ccRCC. In view of these observations it is improbable that G250 functions 
as a oncogene either alone or in combination with (un)known oncogenes. 
The suggestion by Pastorek et al. that G250 can function as an oncogene 
is based on transfection experiments with NIH3T3 cells (Pastorek, 1994). It 
is possible that transfection with a functional carbonic anhydrase leads to 
survival benefit and improved adaptation to conditions generally used to 
demonstrate the effect of a putative oncogene. However, G250 expression 
does not provide an enhanced malignant potential in vivo (pers. 
observations).
By Northern blot analysis a strict correlation between G250 antigen 
and RNA expression was found in primary tissues and cell lines (Appendix 
1). This observation was highly suggestive for transcriptional regulation of 
the G250 gene activation. Therefore the G250 promoter region was studied 
in detail to try to unravel molecular mechanisms leading to G250 
expression (Appendix 4). Sequence analysis of a 1.1 kb 5’ upstream region 
revealed numerous transcription factor (TF) binding consensus sites. This 
included TF binding sequences known to be responsive to acidic stress, 
e.g. TF AP1 (Appendix 4). In tumors the acid-base balance is disturbed: 
insufficient (neo-) vascularization results in hypoxic regions. Cells in these 
hypoxic areas depend on anaerobic glycolysis leading to increased lactate
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production and eventually acidification of tumor tissues (Tannock and 
Rotin, 1989). The expression of G250 in several tumor types and its 
possible role in maintenance of acid-base balance suggested that it might 
be activated in response to acidic stress. However, acidification of tissue 
culture media (pH 7.5-6.3) did not consistently alter G250 protein 
expression: in 5 cell lines (SK-RC-7; SK-RC-59; HS746T; Kato; AGS) G250 
expression was not altered, in 1 cell line G250 expression was decreased 
(ST42) and in 3 cell lines it was increased (HeLa; Alva31; A431) (pers. 
observation). The inconsistency between extracellular pH levels and G250 
expression contradicts the hypothesis that the acidic environment in tumors 
activates G250 expression.
One of the mechanisms leading to gene activation and repression is 
methylation of (specific) CpG dinucleotides, generally located in CpG 
islands (Robertson and Jones, 2000; Baylin, 1998). To investigate whether 
this mechanism played a prominent role in G250 gene activation, the 
methylation status of 9 CpG dinucleotides located at -85 to +216 were 
studied in RCC cell lines (Appendix 2) and paired RCC normal kidney 
specimens (Appendix 3). Isolated DNA was subjected to bisulfite treatment 
followed by PCR and automated sequence analyses. In RCC cell lines, a 
clear-cut inverse correlation between CpG methylation status and G250 
expression was seen. Almost all CpG dinucleotides investigated were 
methylated in G250-negative RCC cell lines, whereas the inverse was 
detected in G250-positive cells (Appendix 2). The clear correlation 
suggested transcriptional regulation of the G250 gene by CpG methylation.
Since it is well documented that, amongst others, CpG methylation 
can alter after in vitro propagation we investigated the CpG methylation 
status of the 9 CpG dinucleotides in paired RCC/ normal kidney specimens 
(Appendix 3; Robertson and Jones, 2000). Surprisingly, in contrast to the in 
vitro findings, CpG methylation was observed in the vast majority of 
samples investigated, without any association with G250 expression. Short­
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term culture of a surgical RCC specimen demonstrated CpG demethylation, 
showing that also in this case CpG methylation had altered due to in vitro 
culture conditions. This demethylation was accompanied by a decrease in 
G250 expression, the reverse phenotype of G250-negative RCC cell lines. 
It is possible that after a crisis where after the cells can be viewed as an 
established cell line, the G250/CpG phenotype converts to either G250- 
positive/CpG-demethylated or the reverse phenotype. Alternatively, only 
the G250-positive/CpG-demethylated or reverse phenotypes can be 
established as cell line.
Since the general activation mechanisms associated with 
carcinogenesis were ruled out as major regulatory events, a detailed 
analysis of the G250 promoter was performed (Appendix 4). The G250 
transcription start site was determined by RNAse protection analysis. The 
G250 gene contains one major transcription start site located 32 
nucleotides upstream of the translation start ATG and several minor 
transcription start sites (Appendix 1). The major transcription start site was 
20 nucleotides longer than that determined by Pastorek et al. and 10 
nucleotides shorter than that determined by Opavsky et al. (Opavsky, 1996; 
Pastorek, 1994). Neither of these start sites contain an initiator consensus 
sequence (Smale, 1997). For functional analysis of the G250 promoter a 
construct containing -1070/+31 of the G250 5’ region (relative to the 
transcription start site, Appendix 1) was isolated (Appendix 4). This region 
showed high promoter activity in G250- positive RCC cell lines and no 
promoter activity in G250-negative RCC cell lines (Appendix 4). Thus 1.1 kb 
of G250 5’ sequences contained G250 specific promoter activity.
To delineate regulatory elements within the G250 promoter various 
truncated constructs were cloned and tested (Appendix 4). Several 
regulatory elements, activating as well as inhibitory, were defined in G250- 
positive RCC cell lines. Remarkably, none of the constructs showed 
promoter activity in G250-negative RCC cell lines, i.e., the G250 promoter
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appears to lack so-called basal promoter activity, able to direct transcription 
in every cell type independent of tissue specific transcription factors. 
Promoter construct -120/+31 showed the highest promoter activity.
Kaluz et al. described a repressor region at -144/-120 in HeLa or 
MaTu cells (lymphocytic choriomeningitis virus infected breast tumor cell 
line (Reiserova, 1999; Widmaier, 1974)): a quantitative difference was 
observed in EMSA when G250-positive and G250-negative HeLa- 
derivatives were compared (Kaluz, 1999). However, this repressor region 
did not seem to regulate G250 expression in RCC cells, since no 
quantitative difference in binding to this region between G250-positive and 
G250-negative RCC cells was observed by EMSA (pers. observation). By 
footprint analysis this region bound transcription factor Sp1 and it is 
possible that different Sp1 family members bind in RCC and in HeLa cells 
(Appendix 4).
By sequence analysis, the smallest construct with G250 promoter 
activity (-60/+31) contained consensus binding sites for transcription factors 
Sp1, AP2, HIF and NFkB (Appendix 4). By EMSA analysis 3 protein 
complexes bound to this region in both G250-positive and G250-negative 
RCC cells. By supershift experiments with Sp1-specific antibody and 
footprint analyses, transcription factor Sp1 was shown to bind to the 
regions -60/-37 and -145/-115 (Appendix 4). To study the importance of the 
proximal Sp1-binding site, site-directed mutated constructs were tested for 
promoter activity. Mutation lead to a virtual absence of promoter activity, 
demonstrating that G250 transcription is strongly dependent on this Sp1- 
binding site (Appendix 4).
In addition to the Sp1 containing complex two non-Sp1 containing 
complexes bound to -60/+31. Initial EMSA experiments did not show HIF- 
binding to -60/+31. However, binding of HIF transcription factor to -27/-8 
could be demonstrated in supershift analyses (pers. observation). Similar to 
Sp1, site-directed mutation of the HIF consensus sequence lead to a virtual
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absence of G250 promoter activity (Appendix 4). The relative importance of 
Sp1 and HIF was equivalent: mutation of either the Sp1 or HIF binding site 
abolished G250 promoter activity (Appendix 4).
The Sp1 binding site partly overlaps an AP2 binding sequence as 
determined by sequence analysis. To determine the possible involvement 
of AP2 in the transcriptional regulation of G250, the Ap2 sequence was 
mutated whereas the Sp1 sequence remained intact. Promoter studies did 
not show any change in promoter activity when the AP2 site was mutated, 
suggesting that AP2 is not involved in G250 promoter activity (Appendix 4).
In addition to the Sp1, HIF and Ap2 consensus binding sites the 
smallest region with G250 promoter activity contained a consensus binding 
site for NFkB. Binding of NFkB to a G250 probe containing the putative 
NFkB binding site was not detected (pers. observation). In conclusion: for 
G250 activation in RCC cells both transcription factors Sp1 and HIF are 
essential.
The involvement of Sp1 and HIF transcription factors in activation of 
the G250 promoter has also been shown in HeLa and CHO cells, but with 
some dissimilarities (Wykoff, 2000; Kaluzova, 1998). In HeLa cells Sp1, 
Sp3, and an unidentified transcription factor complex bind to region -55/-34 
that contains consensus binding sites for Sp1, Ap2, and a CACCC-box 
sequence (Kaluzova, 1998). It is possible that in RCC cells one of the non- 
Sp1 containing complexes binding to region -60/+31contains Sp3. Deletion 
or mutation of the Sp1 binding site decreases G250 promoter activity in 
HeLa cells, but not as dramatically as in RCC cells (Appendix 4; Kaluzova, 
1998). This might be explained by a different regulation of the G250 
promoter in HeLa and RCC cells. E.g. in HeLa cells Sp3 may partially 
repress the activation of G250 transcription by Sp1, leading to a less 
dramatic decrease in G250 promoter activity when the binding site is 
mutated or deleted.
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The transcription factor Sp1 is a ubiquitously expressed Zinc-finger 
transcription factor regulating the constitutive and inducible expression of 
many genes. Thus it is unlikely that different Sp1 levels or activity regulate 
the activation of G250 expression in RCC cells. The VHL gene product, 
functionally deficient in ccRCC, can regulate Sp1 transcriptional activity 
either directly or via PKCZ mediated phosphorylation of Sp1 (Pal, 1998; 
Cohen, 1999; Mukhopadhyay, 1997). It is possible, but not likely, that in 
RCC cells inactivation of the VHL gene product derepresses Sp1 activity 
resulting in (partial) activation of G250 transcription.
We showed that in addition to Sp1 the hypoxia inducible TF HIF is 
essential for G250 activation in RCC cells (Appendix 4). HIF has been 
defined as an essential mediator in the response of cells to hypoxia, 
regulating the transcription of genes involved in angiogenesis, energy 
metabolism, erythropoiesis, cell proliferation, viability, vascular remodeling 
and vasomotor responses (Semenza, 2000a). This TF is a heterodimer 
consisting of the hypoxia inducible HIFa and constitutively expressed HIFb 
subunits (Semenza, 2000a). These proteins are members of the bHLH- 
PAS TF family, containing a basic helix-loop-helix (bHLH) domain required 
for DNA binding and dimerization and a PER-ARNT-SIM homology domain 
(PAS) also involved in dimerization (Semenza, 2000a). Three hypoxia 
inducible a subunits have been described: HIF-1a, HIF-2a 
(EPAS1/HLF/HRF/MOP2) and HIF-3a that can dimerize with one of the b 
subunits: ARNT1 (aryl hydrocarbon receptor nuclear translocator1=HIF-1b), 
ARNT2 or ARNT3 (Semenza, 2000a). The expression and transcriptional 
activity of the a subunit determine the biological activity of the HIF TF. 
Under normoxic conditions the half-life of HIFa subunits is 5-20 minutes: 
this protein is continuously targeted to the proteasome for degradation by 
ubiquitination by the VHL ubiquitin ligase complex (Fig. 2) (Semenza, 
2000b). This pathway also explains G250 activation in ccRCC: ccRCC
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contain an inactivated VHL gene leading to constitutive expression of the 
TF HIF.
In RCC cells binding of HIF to the G250 promoter was essential for 
G250 expression (Appendix 4). Wykoff et al. demonstrated that in a HIF 
deficient subclone of CHO cells cotransfection of either HIF-1 a or HIF-2a 
could restore G250 promoter activity (Wykoff, 2000). Since HIF-2a is the 
most abundant isoform expressed in ccRCC, it is likely that HIF-2a and 
possibly HIF-1 a regulate the transcription of G250 in RCC in conjunction 
with Sp1 (Talks, 2000; Turner, 2002).
Our promoter studies showed that both Sp1 and HIF transcription 
factors are essential for G250 expression (Appendix 4). This indicates that 
a critical cooperation between Sp1 and HIF exists that may involve the 
binding of an essential transcriptional cofactor (complex) to the G250 
promoter. A cofactor independently shown to bind these two transcription 
factors is the histone acetylase CBP/p300 (Liu and Simpson, 1999; Kallio, 
1998; Carrero, 2000; Sang, 2002). Indeed, hypoxic activation of HIF1a is 
dependent on the interaction between HIF1a and CBP/p300 (Kallio, 1998; 
Sang, 2002). This interaction involves an asparagine residue of HIF1a that 
is not hydroxylated under hypoxic conditions (Freedman, 2002; Dames,
2002). However, ccRCC cells sense only one hypoxic signal, i.e. 
stabilization of the HIFa protein, but all other hypoxia-related signals, e.g. 
block of asparagines hydroxylation, are missing (Fig. 2). Thus, the signal 
for recruitment of CBP/p300 in normoxic ccRCC cells may be very weak. 
Under these conditions the cooperation between Sp1 and HIF could be 
essential for the transcriptional activation of G250. Cotransfection 
experiments using E1A and E1A mutants deficient in CBP/p300 interaction 
showed that this cofactor is indeed involved in G250 transcription in RCC 
cells (Appendix 4). However, E1A does not completely block G250 
transcription indicating that other transcriptional (co-) factor(s) may be 
involved, possibly SRC-1. SRC-1 possesses intrinsic histone
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acetyltransferase activity and has been shown to interact with and regulate 
the transcriptional activation of HIF1a (Carrero, 2000).
Our current working hypothesis in ccRCC is that the functional 
inactivation of VHL stabilizes HIF that cooperates with Sp1 in recruiting the 
cofactor CBP/p300 to activate the expression of G250 (Fig. 2). The 
inactivation of VHL is an early event in ccRCC carcinogenesis (Lubensky, 
1996). Similarly, G250 expression is an early event in the malignant 
transformation of proximal tubular cells: homogeneous G250 expression 
was observed in all cells of very small clear cell RCC adenomas (0.2-2 cm 
diameter lesions in cadaver kidneys, E. Oosterwijk, pers. observation). 
Furthermore, transfection of a VHLwt expression vector into a VHLmut 
G250-positive RCC cell line abrogated G250 expresssion and dramatically 
reduced G250 promoter activity (pers. observations). This pathway of VHL 
gene inactivation, constitutive expression of the TF HIF and consequently 
expression of G250 may also be involved in the subset of sporadic ccRCC 
where VHL aberrations cannot be detected (Brauch, 2000). Since G250 is 
expressed in all ccRCC another component of the VHL-HIF pathway may 
be inactivated or alternatively, a component of a VHL-independent pathway 
that stabilizes HIF is activated (Clifford, 2001).
In non-ccRCC this VHL-HIF-G250 pathway can also explain the 
patchy expression of G250. In these tumors the cells exposed to hypoxia 
will stabilize the HIF TF and express the G250 antigen. Indeed, various 
non-RCC cell lines can induce G250 expression upon exposure to a 
chemical hypoxia mimic: CoCl2 (pers. observation). In CHO cells the 
hypoxic upregulation of G250 transcription has been shown to depend on 
HIF transcription factors (Wykoff, 2000). Furthermore, G250 expression in 
non-RCC tumor cells is correlated with hypoxic conditions and markers 
such as the distance from blood vessels, VEGF expression and 
pimonidazol adduct formation (Beasley, 2001; Wykoff, 2000).
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G250 expression is also detected in a limited number of normal cells 
(Oosterwijk, 1995) (Pastorekova, 1997). Since it is unlikely that these cells 
are constitutively exposed to hypoxia, G250 expression may be regulated 
by non-hypoxic stabilization of HIF and/or Sp1. E.g., G250 expression has 
been detected in gastric mucosa cells and gastrin has been shown to 
increase Sp1 levels and DNA binding activity. Furthermore, non-hypoxic 
stabilization of HIF-1a by hormones has been described (Richard, 2000). 
Further research into these non-hypoxic HIF and Sp1 activation pathways 
will probably elucidate G250 activation mechanism(s) in normal cells.
In conclusion, we unraveled the mechanism(s) of activation of the 
G250 gene in ccRCC. The ubiquitous TF HIF and possibly also the 
ubiquitous TF Sp1 are stabilized by ccRCC specific inactivation of the VHL 
gene product. Since HIF is only partially activated in ccRCC a cooperation 
between Sp1 and HIF is necessary to recruit an essential (co)factor and 
activate G250 expression. In non-RCC tumors hypoxia leads to the full 
activation of HIF, recruitment of the (co)factor CBP/p300 and activation of 
G250 expression. In normal cells G250 expression may be regulated by 
unidentified non-hypoxic HIF activation pathways.
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Figure 2 Control of H IFa activation. In hypoxic cells HIFa shuttles to the nucleus 
activating the transcription of oxygen-regulated genes through recruitment of the 
coactivator CBP/p300. In normoxic cells HIFa is hydroxylated at Pro-402, Pro-564 and 
Arg-803 by prolyl and arginine hydroxylases. Hydroxylated HIFa is ubiquitinated by the 
VHL E3 ligase complex and subsequently degraded by the proteasome. In ccRCC 
inactivation of VHL leads to stabilization of HIFa, but recruitment of CBP/p300 is 
hampered by normoxic hydroxylation of Arg-803.
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S u m m a r y
Renal cell carcinoma (RCC) express a number of tumor-associated antigens 
not expressed in normal kidney tissue that might be involved in renal 
carcinogenesis. Obviously, identification of these targets has been of great 
interest, as they might serve as therapeutic targets. One of the most 
extensively studied RCC-associated antigens concerns the antigen defined 
by mAbG250. This G250 antigen is expressed in all cells of the most 
prevalent subtype of RCC (clear cell; ccRCC), whereas it is not expressed 
in normal kidney tissue and expression in other normal tissues is very 
restricted. G250 antigen is also expressed in 50% of other RCC subtypes 
and in non-RCC carcinomas, albeit that expression in non-RCC carcinomas 
is confined to limited tumor areas, and occurs at a much lower frequency. 
Clinical trials with 131I-labeled mAbG250 in RCC patients have shown that the 
G250 antigen can be used as a therapeutic target. Insight into the function 
and molecular activation mechanism(s) of G250 might lead to the 
identification of additional therapeutic target(s). This thesis describes the 
molecular cloning of the G250 cDNA and gene, and the in vitro and in vivo 
activation mechanism(s).
Chapter 1 is a general introduction on RCC and on classes of 
genes involved in carcinogenic pathways in general and in RCC 
specifically. In general no gene has been identified that is a major 
contributor to RCC carcinogenesis with the exception of VHL. VHL targets 
the transcription factor HIFa for degradation. This transcription factor 
activates transcription of genes important for the reaction to hypoxia. 
Normally, VHL takes care of the degradation of HIFa, but in hypoxic 
conditions HIFa is quickly stabilized and activates transcription of hypoxia
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responsive genes. In the majority of ccRCC VHL is (functionally) inactivated 
at an early stage. This inactivation of VHL leads to constitutive HIFa  
expression and transcription of hypoxia responsive genes. In ccRCC many 
genes are upregulated of which several are under the control of the HIF 
transcription factor.
A gene that is activated in all ccRCC is the G250 gene 
(Section 6.1). This activation indicates that G250 might function as an 
oncogene, a gene that when activated leads to tumor formation. To 
address this possibility the G250 cDNA and gene were cloned (Chapter 2 
and Section 6.2). Several studies including mutation analyses and 
transfection experiments indicate that G250 does not function as an 
oncogene (Section 6.3).
The function of G250 was further investigated by sequence analysis 
(Chapter 2, Section 6.2, and Section 6.3). This showed that G250 is 
located in the cell membrane with the major part of the protein extracellular. 
It is identical to the previously identified cervixtumor-associated antigen 
MN/CAIX. A large part of G250 is homologous to carbonic anhydrases (CA). 
CA are enzymes that catalyze the (inter) conversion of H2O and CO2 into 
HCO3- en H+, thus play an important role in acid-base balance. The CA 
domain in G250 was shown to be functional, raising the possibility that 
G250 maintains acid-base homeostasis in carcinomas. However, 
expression of G250 in cell lines was not correlated with cell culture medium 
pH, suggesting that the CA of G250 functions in ion exchange or transport 
processes (Section 6.3).
Elucidation of the CA function of G250 did not explain the role in the 
carcinogenesis of several tumor types. Insight into the molecular activation 
mechanism(s) of G250 could resolve this question (Chapter 3, Chapter 4,
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Chapter 5 and Section 6.4). A strict correlation between G250 protein and 
G250 mRNA expression was observed. This indicated that G250 
expression is regulated at the transcriptional level: when transcription of the 
gene is activated, G250 mRNA and protein are produced, and vice versa. 
Several mechanisms for this transcriptional activation of the G250 gene 
were investigated.
One mechanism for transcriptional regulation of a gene is by 
(de)methylation of the DNA. In tumors it is well documented that alterations 
in methylation patterns occur throughout the genome. Thus the methylation 
patterns of the G250 gene were determined both in RCC cell lines (in vitro) 
and in paired tumor/normal kidney specimens (in vivo) (Chpater 3, 
Chapter 4 and Section 6.4). In RCC cell lines, a clear inverse correlation 
between G250 methylation and expression was observed, suggesting that 
G250 transcription could be activated by hypomethylation. However, in the 
vast majority of paired RCC/ normal kidney specimens the G250 was 
methylated independent of G250 expression. Thus in vivo hypomethylation 
of the G250 gene is not the transcriptional activation mechanism. The 
observed inverse correlation in vitro seems to be tissue culture induced: a 
short-term culture of a surgical RCC specimen demonstrated decreasing 
methylation.
To further delineate the transcriptional activation mechanism(s) of 
the G250 gene a detailed analysis was performed of the region of the G250 
gene responsible for the regulation of transcription (promoter) (Chapter 5 
and Section 6.4,). In the minimal promoter region that could still activate 
G250 transcription, binding sites for among others the transcription factors 
Sp1 and HIF were predicted. Various analyses showed that these two 
transcription factors do bind to the G250 promoter and that they are
153
Summary
essential for G250 promoter activity. Since Sp1 is a ubiquitous transcription 
factor it is unlikely that it can affect the transcriptional activation of G250 in 
RCC. However, in RCC the HIF transcription factor is constitutively 
activated by the (functional) absence of its negative regulator: VHL. In 
normal kidney tissue VHL is functional, targeting HIF for degradation, 
preventing it to activate G250 transcription.
The G250 transcriptional activation by HIF also explains regional 
G250 expression in non-ccRCC tumors. In these tumors HIF is activated in 
hypoxic areas directing transcription of G250. Also in normal cells G250 
expression may be mediated by activation of HIF through non-hypoxic 
pathways. Further studies into the non-hypoxic HIF activation pathways 
may lead to new therapeutic options.
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S a m e n v a t t i n g
In niercel-tumoren komen tumor geassocieerde eiwitten voor: eiwitten die 
niet voorkomen in normale niercellen en die betrokken kunnen zijn bij het 
ontstaan van het niercel-carcinoom. Daarom is de identificatie van deze 
antigenen van groot belang voor de ontwikkeling van nieuwe therapieën. 
Het antigen dat in deze context het uitgebreidst bestudeerd is, betreft het 
antigen herkend door het monoklonale antilichaam G250. Dit eveneens 
G250 gnoemde antigen wordt gemaakt in alle cellen van het meest 
voorkomende subtype van niercel-carcinomen: het heldercellige niercel- 
carcinoom. Daarentegen is G250 afwezig in normale niercellen en komt 
maar zeer beperkt voor in andere normale weefsels. G250 komt daarnaast 
nog voor in 50% van andere niercel-carcinoom subtypen en nog minder 
frequent in andere carcinomen, waarbij in deze niet-niercel-carcinomen de 
expressie zich beperkt tot bepaalde tumorgebieden. Klinische studies met 
radioactief gelabeld monoklonaal antilichaam G250 hebben laten zien dat 
het G250 antigen als therapeutisch doelwit gebruikt kan worden in niercel- 
carcinoom patiënten. Dit proefschrift verhandelt de moleculaire identificatie 
van het G250 cDNA en gen en de in vitro en in vivo activerings- 
mechanismen in tumoren.
Hoofdstuk 1 is een algemene inleiding op het niercel-carcinoom en 
de gencategorieën die betrokken zijn bij de carcinoomgenese in het 
algemeen en specifieker bij de niercel-carcinoomgenese. Bij deze laatste
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zijn tot nu toe nog geen genen geïdentificeerd die een proces-bepalende 
rol spelen, met uitzondering van het Von Hippel-Lindau (VHL) gen. De 
functie van VHL is het doen afbreken van HIFa, een eiwit dat de expressie 
van bepaalde genen kan activeren (een zgn. transcriptie factor). Deze 
transcriptie factor zorgt voor het afschrijven van genen die van belang zijn 
bij de reactie van de cel op een zuurstoftekort (hypoxie). Onder normale 
omstandigheden zorgt VHL voor de afbraak van HIFa, maar in geval van 
hypoxie wordt HIFa snel gestabiliseerd en kan het de transcriptie van 
hypoxie geassocieerde genen activeren. Zo ook in de meeste heldercellige 
niercel-carcinomen: het VHL gen is (functioneel) geïnactiveerd in een vroeg 
stadium, wat leidt tot een constante HIFa expressie en dus tot transcriptie 
van hypoxie geassocieerde genen. In heldercellige niercel-carcinomen 
komen veel genen verhoogd tot expressie, waarvan verscheidene 
geactiveerd door de HIF transcriptie factor.
Een van de genen die in heldercellige niercel-carcinomen 
geactiveerd is is het G250 gen (hoofdstuk 6). In tegenstelling tot veel 
andere genen is G250 in alle heldercellige niercel-carcinomen geactiveerd. 
Deze activering duidt erop dat G250 zou kunnen functioneren als een 
oncogen, een gen waarvan activering leidt tot tumorformatie. Om hier meer 
inzicht in te krijgen is het G250 cDNA en gen gekloneerd (hoofdstuk 2 en 
paragraaf 6.2). Verscheidene studies waaronder mutatie analyses en 
transfectie experimenten tonen aan dat G250 geen oncogen is 
(paragraaf 6.3).
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De functie van G250 is verder onderzocht door sequentie analyse, 
waarruit de volgende conclusies getrokken kunnen worden. G250 is reeds 
eerder geïdentificeerd als een cervixtumor geassocieerd antigen (MN/CA9). 
Het is een eiwit dat in de celmembraan verankerd is en het grootste 
gedeelte van het eiwit bevindt zich extracellulair. Dit extracellulaire gedeelte 
is homoloog met carbonic anhydrases (CA), enzymen die H2O en CO2 
omzetten in HCO3" en H+. Het CA homologe domein in G250 kan inderdaad 
als CA functioneren en zou daardoor een rol kunnen spelen in de zuur- 
base balans van carcinomen. Echter, expressie van G250 in cellijnen toont 
geen correlatie met de pH van de celkweek media. Omdat G250 dus geen 
rol lijkt te spelen in pH regulatie zou het kunnen functioneren in de 
uitwisseling van ionen of de transport van producten (paragraaf 6.3).
De opheldering van de CA functie van G250 kan de rol die dit eiwit 
speelt in de carcinoomgenese van verscheidene tumoren niet verklaren. 
Inzicht in de moleculaire activeringsmechanisme(n) van G250 zou deze 
vraag kunnen beantwoorden (hoofdstuk 3, hoofdstuk 4, hoofstuk 5 en 
paragraaf 6.4). W e constateerden een strikte correlatie tussen G250 eiwit 
en G250 mRNA expressie, wat erop duidt dat de G250 expressie op 
transcriptioneel niveau geregeld wordt: wanneer de transcriptie van het gen 
geactiveerd is worden G250 mRNA en eiwit aangemaakt en vice versa. 
Daarom zijn verscheidene mechanismen voor de transcriptionele activering 
van G250 onderzocht.
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Een van de mechanismen waarop de transcriptie van een gen 
geregeld kan worden is door het (de)methyleren van het DNA. In tumoren 
komen veranderingen in het patroon van methyleren verspreid door het 
hele DNA voor. Daarom is het methyleren van het G250 gen in zowel RCC 
cellijnen (in vitro) als in RCC tumoren (in vivo) onderzocht (hoofdstuk 3 
hoofstuk 4 en paragraaf 6.4). RCC cellijnen tonen een duidelijke inverse 
correlatie tussen G250 methyleren en expressie, wat suggereerde dat 
G250 transcriptie geactiveerd zou kunnen worden door hypo-methyleren 
van het G250 gen. In tegenstelling tot deze inverse correlatie in de RCC 
cellijnen, blijkt het G250 gen in de meeste tumor/ normale nierweefsels 
gemethyleerd te zijn onafhankelijk van de expressie van G250. In vivo is 
hypo-methyleren van het G250 gen dus geen mechanisme voor activering 
van transcriptie. Dat dit mechanisme wel een rol lijkt te spelen in vitro blijkt 
geïnduceerd te worden door de celkweek condities: wanneer een tumor 
voor korte tijd in celkweek is gehouden, wordt het G250 gen steeds verder 
gedemethyleerd.
Om de transcriptionele activeringsmechanismen van het G250 gen 
verder af te bakenen is het gedeelte van het G250 verantwoordelijk voor de 
regulatie van transcriptie (promoter) onderzocht (hoofdstuk 5 en 
paragraaf 6.4). Voor het kleinste gedeelte van de promoter dat nog steeds 
transcriptie van het G250 gen kon activeren, zijn door een database 
bindingsplaatsen voor onder andere de transcriptie factoren Sp1 en HIF 
voorspeld. Verscheidene analyses hebben laten zien dat deze transcriptie
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factoren ook daadwerkelijk de G250 promoter binden en dat deze 
essentieel zijn voor de G250 promoter activiteit. De transcriptie factor Sp1 
is een algemene transcriptie factor wat het onwaarschijnlijk maakt dat deze 
specifiek in niercel-carcinomen de activering van G250 transcriptie kan 
bewerkstelligen. De HIF transcriptie factor is echter in niercel-carcinomen 
constitutief geactiveerd aangezien zijn negatieve regulator, VHL, 
geïnactiveerd is. In normaal nierweefsel is VHL wel functioneel aanwezig 
en zal ervoor zorgen dat HIF afgebroken wordt, wat activering van G250 
transcriptie verhindert.
De activering van G250 transcriptie door HIF kan ook de regionale 
G250 expressie in niet-niercel-carcinomen verklaren. In deze tumoren 
wordt HIF geactiveerd in gebieden met hypoxie wat leidt tot G250 
transcriptie in deze gebieden. Zelfs in normale cellen zou G250 transcriptie 
geactiveerd kunnen worden door stabilisering van HIF, maar dan 
waarschijnlijk via alternatieve mechanismen. Een beter inzicht in 
alternatieve HIF stabilisatie mechanismen zal de mogelijkheden voor 
therapieën vergroten.
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List of Abbreviations
aa amino acids
APC denomatous polyposis coli
ARNT Aryl hydrocarbon receptor nuclear translocator
bHLH basic Helix Loop Helix
bp base pair
CA carbonic anhydrase
ccRCC clear cell Renal Cell Carcinoma
CHO Chinese Hamster Ovary
CTL cytotoxic T-lymphocyte
DRR1 downregulated in renal cell carcinoma
ds double stranded
EMSA electrophoretic mobility shift analysis
FACS fluorescence activated cell sorting
FHIT fragile histidine triad
FISH Fluorescent in situ hybridization
HAB hemangioblastomas
HIF hypoxia inducible transcription factor
HNPCC Hereditary non-polyposis colorectal cancer
hpv human papilloma virus
LCMV lymphocytic choriomeningitis virus
LOH Loss of Heterozygosity
mAb monoclonal Antibody
OGG1 8-oxoguanine DNA glycosylase
ORF open reading frame
PAAGE polyacrylamid gel electrophoresis
PAS Per Arnt Sim homology domain
PBS phosphate buffered salt solution
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PCR polymerase chain reaction
PHE pheochromocytomas
PKC Protein Kinase C
PTEN Phosphatase and Tensin homologue
RASSF1A RAS association domain family 1A gene
Rb Retinoblastoma
RCC Renal Cell Carcinoma
RT reverse transcriptase
SSCP Single Strand Conformation Polymorphism
TAA tumor associated antigen
TF transcription factor
TßllR TGFß type II receptor
TIL tumor infiltrating lymphocytes
VEGF Vascular Endothelial Growth Factor
VHL Von Hippel-Lindau
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